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Abstract of Thesis 
Background 
The global scenario of hospital pharmacy practice shows that hospital pharmacy practice differs in 
developed and developing countries with the latter often being confined to more primitive product-
centred models. In order to standardise hospital pharmacy practice around the world, international 
guidelines named the Basel Statements were developed by the International Pharmaceutical 
Federation (FIP) and cover six key elements of hospital pharmacy, one of which is medicines 
procurement. Despite disparity in global hospital pharmacy practice, equitable access to affordable 
and evidence-based high quality medicines is a common priority. Accessibility, affordability, safety, 
and quality of medicines are influenced by medicine procurement, therefore making medicine 
procurement one of the most important aspects of healthcare systems. It is believed that developed 
countries are more efficient in managing medicine distribution and have stronger regulatory 
frameworks that contribute to better access to medicines. Meanwhile there is a large proportion of 
people in low-income developing countries like Nepal that are deprived of access to essential 
medicines. Therefore, this study aimed to compare medicine procurement practices in hospitals of 
Australia (a high-income developed country) and Nepal (a low income developing country) based on 
the internationally recognized guidelines, the Basel Statements, with the objective of discovering 
facilitators and barriers to procurement practice and improving current medicine procurement practice 
in Nepal. 
Chapter 1 of this thesis is a literature review conducted to explore medicine procurement issues 
utilising a framework of procurement statements of the Basel Statements. This literature review 
revealed that different aspects of procurement practice have been studied in different ways; however, 
it was found that there were some principles reflected in the Basel Statements in which there were a 
dearth of literature. Furthermore, much of the literature contained opinion pieces and individuals’ 
perceptions of barriers to good procurement practices and there was a lack of scientific studies in the 
field. In regard to Nepal, there were very few studies and information available about medicine 
procurement practice in the country, indicating the need for a thorough study on medicine 
procurement practice and its issues, dissemination of public procurement reports, and other 
procurement related information. 
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Chapter 2 describes the methodology used for the two qualitative studies which comprise chapters 3 
and 4. This chapter provides a short description of semi-structured interviews conducted and the 
framework analysis method and its suitability for this study, as well as the rationale for data division 
into the two manuscripts. 
Chapter 3 contains the manuscript pertaining to a qualitative study about medicine procurement in 
hospital pharmacies of Nepal based on the Basel Statements. This chapter describes the medicine 
procurement procedures, compliance of hospitals to procurement guidelines of the Basel Statements, 
barriers to guideline implementation, and other procurement issues. This study revealed that the 
Basel Statements were implemented to some extent and barriers were reported to be privatisation of 
hospital pharmacies, influences on medicine selection procedures, sole authority of doctors on 
selecting medicines, and inefficient regulatory enforcement. Utilization of expensive procurement 
methods, lack of well-defined procurement procedures, influences on prescription based medicine 
selection, lack of systems for managing relationships between decision makers and pharmaceutical 
companies, lack of strategic preparedness plans, and availability of unregistered medicines especially 
during emergencies in hospital pharmacies near the Indian border were some of the major findings of 
this study. This study indicated that there is a need for improvement in some procurement issues; 
however, hospital pharmacies of Nepal are doing well in some aspects of procurement procedures. 
Chapter 4 contains the manuscript pertaining to a comparative study of medicine procurement 
practices of Australia and Nepal conducted with the objective of discovering good procurement 
procedures and proposing evidence-based recommendations to improve current procurement 
practices of Nepal. The procurement theme of the Basel Statements is used as a reference standard 
to compare guideline compliance rates of public hospital pharmacies in the two countries. As 
expected, guideline implementation rates were higher in Australia compared to that of Nepal. 
Variation in procurement elements such as procurement methods, medicine selection processes, 
relationships between decision makers and pharmaceutical companies, contingency plans, the 
working culture, and perceptions of key stakeholders were evident between Australian and Nepalese 
procurement practices. However, some comparable factors were also reported; information 
resources, storage facilities, quality assurance principles, and expertise involvement in the 
procurement process were common to both settings. Whilst it is understood that procurement 
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procedures of Nepal need some improvements to be in line with international standards, attempts of 
hospital pharmacies of Nepal in implementing national procurement guidelines and practising good 
procurement procedures are gaining momentum and some elements of current practice are 
satisfactory.  Utilization of international guidelines and successful strategies of Australian practice 
adapted to fit country’s needs and capacities is recommended for Nepal.  
Chapter 5 is a concluding chapter that summarizes and discusses major findings of this research and 
proposes recommendations for improving procurement practice in Nepal. Procurement issues, 
barriers to guideline implementation, and possibilities of improvements were summarised in this 
research. The comparative study provided insights into how developed countries like Australia are 
conducting effective procurement practices that meet international standards and how this country 
has been successful in providing equitable access to affordable and high-quality medicines to its 
population. Having said this, it was encouraging to see that there were good elements of procurement 
procedures also reported from Nepalese practice suggesting the progressive nature of procurement 
practices in Nepal. Good procurement procedures such as e.g. group contracting strategies, 
formulary systems, well-managed relationship between doctors/pharmacists and pharmaceutical 
companies are amongst many recommendations for Nepal to consider. Therefore, amendments of 
existing guidelines to incorporate missing elements and strengthening enforcement of national 
policies and guidelines would be recommended as a starting point for Nepal to work towards better 
practice. In addition to this, adoption and adaption of international guidelines to suit national 
requirements, resources and capacities are highly recommended for Nepal that would advance the 
current procurement practice to meet international standards. 
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Background to this Thesis 
Medicines are the primary vehicle for healthcare delivery and have huge impact on 
the health and well-being of people around the globe [1-3]. Medicines, in conjunction 
with other healthcare services, assist in treating diseases, promoting quality of life, 
and minimizing mortality rates [4]. Equitable access to affordable and quality 
medicines is therefore considered as a fundamental human right [5] and one of the 
targets of the Sustainable Development Goals [6] . Equitable access to medicines is 
also vital for achieving several other Sustainable Development Goals (SDGs) such 
as minimizing child death, improving maternal health and fighting against diseases 
like HIV/AIDS and tuberculosis [1-3, 6].  
Costs of medicines utilize a large proportion of total health expenditure, especially in 
developing countries where expenditure could be as high as 60% of total health 
expenditure, making access to health care heavily reliant on availability and 
affordability of medicines [1, 7-9]. The World Health Organization (WHO) has 
emphasized the importance of availability, affordability, quality and safety of 
medicines for saving lives and improving health [4]. However, more than half of the 
population in low-income countries in Africa and Asia do not have regular access to 
essential medicines, either due to lack of regulatory authority or limited capacity to 
regulate medicines distribution [1, 8, 9]. Although the Essential Medicines List (EML) 
Programme of WHO has been hugely successful in improving accessibility of 
essential medicines in many low and middle-income countries, access to medicines 
is still a vast global problem, particularly for underprivileged populations [10]. Due to 
poor availability of medicines in the public sector, high prices in private sectors, and 
lack of universal healthcare in many low-income countries, medicines tend to be 
unaffordable for the majority of the population in these countries [8]. This causes lack 
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of access to medicines and healthcare, which can lead to loss of income and 
increase in healthcare cost creating a never ending poverty cycle for poor and 
underprivileged populations [11]. 
One such country with poor accessibility and affordability of essential medicines [12] 
in South-Asia is Nepal, which is categorized by the World Bank in the low-income 
group [13]. It is a landlocked country with a population of 28.17 million [14] with a 
Gross National Income (GNI) per capita (Atlas method) of US$730 [14]. This is half 
of the average South Asian value of US$1496, lower than average least-developed 
countries value of US$844 and much lower than the global value of US$10787 [15]. 
Nepal ranks 145th in Human Development Index (HDI) with 0.540  value (2014) [16] 
and has Gross Domestic Product (GDP) growth of 5.4% (2014) [14], forcing 25.2% 
of its population to live under the poverty line [13].  With 5.69% of Nepal’s GDP spent 
on health [17], the health status of Nepal is poor, and life expectancy at birth is only 
68 years [13]. The adult mortality rate is 176 per 1000 population [18] and the under-
five mortality rate is 35.8 per 1000 live births [19].  
Health services in Nepal are provided mainly by three types of healthcare facilities: 
governmental institutions, non-governmental and non-profit organizations, and 
private health institutions [20]. Availability of medicines is poor in public health 
institutions, whilst prices of medicines are 66.3% higher in private health institutions 
of Nepal [21]. The government health expenditure accounted for 39.04% of total 
expenditure (including 33.8% contribution from external development partners and 
donor organizations) and private health expenditure covered the remaining 60.96% 
of total health expenditure [17, 22]. The government and donor organizations provide 
funding for selected healthcare services and freely distributed essential medicines 
and patients then have to pay for all other healthcare facilities and medicines [22, 23] 
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which in total means that out-of-pocket expenditure comprises of 48.68% of total 
health expenditure [17].  
WHO has recommended rational selection and use of essential medicines, 
affordable prices, sustainable financing, and reliable health supply systems to 
improve accessibility of essential medicines [4, 9]. 
 
Figure 1: Access framework (adapted from WHO 2004) [4] 
Similarly,  Bigdeli et al. (2013) (Figure 2) have also proposed recommendations 
which emphasised improving affordability, perceived quality of medicines and 
attitudes of healthcare providers, health financing and resources, policy reforms, 
pharmaceutical innovations, transparency, and external funding system [10]. These 
factors included in recommendations from WHO and Bigdeli et al. constitute 
elements of the procurement process [24-26].  
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Figure 2: A conceptual framework of Access to Medicines  (adapted from Bigdeli 
et al., 2013) [10] 
Much research has been conducted to identify barriers and recommend solutions to 
the lack of access to medicines for those in need, and a common element among 
them has been improvements in medicine procurement processes [8, 9, 11, 27, 28].  
Procurement can be defined as the process of acquiring supplies through purchase 
from manufacturers or suppliers or distributors [1]. Medicine procurement has a huge 
influence on accessibility and affordability of evidence-based high quality medicines 
[1]. In addition to this, efficient medicine procurement systems have a significant 
influence on the overall functioning of healthcare systems [1]. The Organisation for 
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Economic Co-operation and Development (OECD) in 2005 has also emphasized the 
importance of efficient public sector procurement systems in achieving the 
Millennium Development Goals and sustainable development [27]. Thus, medicine 
procurement is considered an essential element of healthcare and the health 
economy, due to its huge impact on total health expenditure and quality, safety, 
availability and affordability of medicines [1, 7]. Effective procurement is critical for 
efficient medicine management and supply systems in any healthcare institution [1]. 
It is often a complex and specialized process involving a series of interdisciplinary 
processes under the supervision and involvement of persons with different expertise 
[1]. An effective procurement process should ensure availability of the right 
medicines in the right quantities, at the right time, for the right patients at reasonable 
prices, and at recognizable standards of quality [1]. Moreover, an effective 
procurement procedure should be able to assure the quality of medicines procured, 
manage timely delivery of medicines to avoid shortages and over stock, manage 
transparent and ethical relationship between suppliers and decision-makers, and 
select reliable suppliers [25]. The procurement process is illustrated in Figure 3. 
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Figure 3: Procurement Cycle (adapted from MSH 2012) [25] 
Procurement procedures may vary depending on the types of health institutions [25] 
and may utilize one or a combination of the following strategies: 
1. Centralized Procurement governed by the central government [27]. 
2. Parastatal Organization or Autonomous Supply Agency, in which 
procurement is controlled centrally by an independent agency which is wholly 
or partly owned or regulated by the government [27]. 
3. Decentralized Procurement that works locally at the regional, district or 
municipal levels [27]. 
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4. Procurement Agents, in which procurement procedures are carried out by 
independent procurement agents to assist government or as a requirement of 
funding organizations [27]. 
5. Direct Delivery, in which procurement is managed centrally but delivery is 
decentralized and occurs directly to individual health institution [4]. 
6. Fully Private Supply is a decentralized system that is managed by private 
organizations [4]. 
Procurement in Nepal differs, depending on whether the health institution is 
governmental, a non-profit organization or a private institution. Public procurement in 
Nepal is conducted in three different ways: central push/pull systems, district level 
drug programs, and community drug programs [29]. 
Procurement methods can be categorised into four basic types: open tender, 
restricted tender, competitive negotiations (including local and international 
procurement) and direct procurement [25]. Definitions of each type are listed below. 
Open Tender is a type of competitive process which is open to all local and 
international suppliers with predefined terms and conditions [25].  
Restricted Tender: In this type of tendering process, tender is restricted to 
suppliers that have been approved through a prequalification process conducted 
by procurement agency. This is also applicable to locally licensed manufacturers 
or importers which have been prequalified by national medicines regulatory 
authorities and analyses manufacturing and analytical procedures, compliance to 
national and international regulations, performance of suppliers, and financial 
viability [25]. 
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Competitive Negotiations: In this method, a limited numbers of suppliers are 
contacted and asked for price quotations and are later  subjected to a process of 
price negotiations. This can occur at local and international level. This method is 
usually utilized by private organizations, as public procurement might not allow 
bargaining with suppliers [25].  
Direct Procurement: The simplest but most expensive method involves direct 
purchasing from a single supplier at either an allocated price or negotiated 
discount price. Purchase of medicines with a single source supplier is usually 
conducted through this procurement method [25]. 
Each category has both advantages and disadvantages (Table 1) [30]. 
Table 1: Procurement Methods  
Procurement Method Advantages Disadvantages 
Open tender Higher number of bidders, 
more competitive price, and 
discovery of new potential 
suppliers 
Higher workloads for 
evaluation and selection 
Restricted tender Relatively fewer bidders, 
prequalification of suppliers, 
easier for evaluation 
Limited choices 
prequalification system 
should be designed 
Competitive 
negotiations 
Well-known suppliers 
therefore easy and less 
work 
Relatively higher prices 
Direct procurement Easy and quick Higher prices 
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Selection of procurement methods is generally influenced by funding mechanisms, 
procurement policies and regulations, quality assurance systems, price of medicines, 
expertise involvement, and capabilities of management [27]. Written guidelines 
should be made available to the committee and the procurement staff in helping to 
choose the best procurement method for a given product, to obtain the lowest 
possible purchase price for assured quality from reliable suppliers [1]. Public 
hospitals of Nepal are encouraged to procure medicines in accordance with the 
Public Procurement Guidelines. The Public Procurement Guidelines published by 
Ministry of Health and Population, Government of Nepal provides detailed stepwise 
description on formulating procurement unit and necessary sub-committees, 
selecting appropriate procurement methods depending on quantity and nature of 
goods/services, carrying out procurement process, and conducting evaluation 
process. The guideline advocates for competitive and open tendering process to 
purchase of low-cost quality products and gives high preference for goods 
manufactured locally in Nepal, even the price is higher up to 10%. Although, this is a 
general guideline applicable to all products/services purchased, special evaluation 
criteria have been formulated for medicines [31].  
In relation to procurement specifically, the WHO has recognized the following issues 
as major problems associated with procurement of medicines [24]: 
 Inadequate rules, regulations and structures 
 Public sector staff with little experience in responding to market situations 
 Absence of a comprehensive procurement policy 
 Insufficient and irregular government funding 
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 Conflicting procurement regulations of donor agencies 
 Fragmented provincial or district levels procurement system (decentralized 
system) 
 Lack of unbiased market information 
 Lack of trained procurement staff  
The aim of this study was to explore the issue of medicine procurement in hospital 
pharmacies of Nepal, compare medicine procurement practices of hospital 
pharmacies between Nepal and Australia, and propose evidence-based 
recommendations to overcome existing barriers, to improve current procurement 
practice.  
Although Nepal has the Public Procurement Act and Guidelines [31, 32], National 
Medicine Policy [33], and Hospital Pharmacy Directives [23], these policies and 
guidelines do not address medicine procurement in much detail. Moreover, the 
country does not have any specific medicine procurement-related policies and 
guidelines.  
In order to compare medicine procurement practices between two different countries, 
an international standard which could suit practices of both countries was needed. 
The FIP Basel Statements are international guidelines that standardise the global 
hospital pharmacy practice and medicine procurement is one of the themes included. 
The Medicine Procurement theme of the Basel Statements provides guidance on 
procurement procedure in hospital pharmacy and advocates for transparency, 
professional and ethical procurement practice that leads to timely purchase of high-
quality, affordable and safe medicines under the supervision of skilled and qualified 
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personnel. The Basel Statements were therefore selected as reference standards for 
exploring medicine procurement in hospital pharmacies of Nepal. Additionally, we 
aimed to analyse compliance of procurement practices with medicine procurement-
related policies that have been included in national policies and guidelines of Nepal.  
The work outlined in Chapter One pertains to a review of the literature regarding 
medicine procurement practices with reference to procurement guidelines of the 
Basel Statements.  
Chapter Two outlines qualitative methods used to interview pharmacists from both 
Nepal and Australia.  
Chapters Three and Four then outline the findings of the qualitative work, and have 
been inserted in manuscript format as they have been submitted for publication.  
Finally, the thesis concludes with Chapter Five which draws this original work 
together and concludes with recommendations for Nepal. 
 
 
 
 
 
 
 
 
Background to this Thesis 
 
13 
 
References 
1. Baghdadi‐Sabeti G, Cohen‐Kohler JC, Wondemagegnehu E. Measuring 
Transparency in the Public Pharmaceutical Sector. World Health 
Organization. 2009.  Available from: 
http://apps.who.int/medicinedocs/documents/s16732e/s16732e.pdf. Accessed 
2 February 2016. 
2. Doloresco F, Vermeulen LC. Global Survey of Hospital Pharmacy Practice. 
Am J Health Syst Pharm. 2009. 66(5 Suppl 3):S13-9. 
3. Hogerzeil HV. Essential Medicines and Human Rights: What Can They Learn 
from Each Other? Bull World Health Organ. 2006. 84(5):371-5. 
4. World Health Organization. Equitable Access to Essential Medicines: A 
Framework for Collective Action. WHO Policy Perspectives on Medicines. 
2004.1-6. 
5. Office of the United Nations High Commissioner for Human Rights, World 
Health Organization. The Right to Health. United Nations. 2008.  Available 
from: http://www.who.int/hhr/activities/Right_to_Health_factsheet31.pdf. 
Accessed 4 February 2016. 
6. The United Nations. Sustainable Development Goals. UN Web Services 
Section, Department of Public Information, United Nations. 2015.  Available 
from: http://www.un.org/sustainabledevelopment/health/. Accessed 4 
February 2016. 
7. Ombaka E. Current Status of Medicines Procurement. Am J Health Syst 
Pharm. 2009. 66(5 Suppl 3):S20-8. doi: http://dx.doi.org/10.2146/ajhp080604. 
8. Cameron A, Ewen M, Auton M, Abegunde D. The World Medicines Situation 
2011: Medicines Prices, Availability and Affordability. World Health 
Background to this Thesis 
 
14 
 
Organization. 2011.  Available from: 
http://apps.who.int/medicinedocs/documents/s18065en/s18065en.pdf 
Accessed 5 February 2016. 
9. World Health Organization. Access to Medicines. World Health Organization. 
2016.  Available from: http://www.who.int/trade/glossary/story002/en/. 
Accessed 3 January 2016. 
10. Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access 
to Medicines from a Health System Perspective. Health Policy Plan. 2013. 
28(7):692-704. doi: 10.1093/heapol/czs108. 
11. Peters DH, Garg A, Bloom G, Walker DG, Brieger WR, Hafizur Rahman M. 
Poverty and Access to Health Care in Developing Countries. Ann N Y Acad 
Sci. 2008. 1136(1):161-71. doi: 10.1196/annals.1425.011. 
12. Babar ZU, Lessing C, Mace C, Bissell K. The Availability, Pricing and 
Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-
Income Countries. Pharmacoeconomics. 2013. 31(11):1063-82. 
13. The World Bank. Nepal. The World Bank Group. 2015.  Available from: 
http://data.worldbank.org/country/nepal. Accessed 6 February 2016. 
14. The World Bank. World Development Indicators: Nepal. The World Bank 
Group. 2015.  Available from: 
http://databank.worldbank.org/data/reports.aspx?source=2&country=NPL&ser
ies=&period=. Accessed 6 February 2016. 
15. The World Bank. Economy and Growth. The World Bank Group. 2014.  
Available from: http://data.worldbank.org/topic/economy-and-growth. 
Accessed 6 January 2016. 
Background to this Thesis 
 
15 
 
16. United Nations Development Programme. 2014 Human Development Report. 
United Nations Development Programme. 2015.  Available from: 
http://www.undp.org/content/undp/en/home/librarypage/hdr/2014-human-
development-report/. Accessed 8 February 2016. 
17. World Health Organization. Health Expenditure Ratios, All Countries, Selected 
Years Estimates by Country. 2013.  Available from: 
http://apps.who.int/gho/data/node.main.75?lang=en. Accessed 5 February 
2016. 
18. World Health Organization. Adult Mortality Data by Country. World Health 
Organization. 2015.  Available from: 
http://apps.who.int/gho/data/view.main.1360?lang=en. Accessed 5 February 
2016. 
19. World Health Organization. Probability of Dying Per 1 000 Live Births Data by 
Country. World Health Organization. 2015.  Available from: 
http://apps.who.int/gho/data/node.main.ChildMort-2?lang=en. Accessed 5 
February 2016. 
20. Dixit H. The Quest for Health: The Health Services of Nepal. Kathmandu: 
Educational Enterprise (P) Limited; 1999. 
21. Mendis S, Fukino K, Cameron A, Laing R, Filipe Jr A, Khatib O, et al. The 
Availability and Affordability of Selected Essential Medicines for Chronic 
Diseases in Six Low- and Middle-Income Countries. Bull World Health Organ. 
2007. 85(4):279-88. doi: 10.2471/BLT.06.033647. 
22. Government of Nepal, Ministry of Health and Population. Current Status of 
Mohp's Annual Work Plan and Budget. Government of Nepal, Ministry of 
Health and Population. 2013.  Available from: 
Background to this Thesis 
 
16 
 
http://www.mohp.gov.np/images/pdf/publication/Budget-Analysis-2070-71.pdf. 
Accessed 6 February 2016. 
23. Government of Nepal, Ministry of Health and Population. Hospital Pharmacy 
Directives. Government of Nepal, Ministry of Health and Population. 2013.  
Available from: http://www.slideshare.net/niraj_bartaula/hospital-pharmacy-
service-directives-2070-55955345. Accessed 3 February 2016. 
24. Rankin J, Quick JD, Muziki. S, Woldeyesus K, Fresle DA, Grayston G, et al. 
Operational Principles for Good Pharmaceutical Procurement. WHO’s 
Department of Essential Drugs and Medicines Policy (EDM). 1999.  Available 
from: http://www.who.int/3by5/en/who-edm-par-99-5.pdf. Accessed 6 
February 2016. 
25. Barraclough A, Clark M. Managing Procurement. 2012. In: Managing Access 
to Medicines and Health Technologies [Internet]. Arlington, VA: Management 
Science for Health.  [18.1-.26].  Available from: 
http://apps.who.int/medicinedocs/documents/s19577en/s19577en.pdf. 
Accessed on 7 February 2016. 
26. The Basel Statements on the Future of Hospital Pharmacy. Am J Health Syst 
Pharm. 2009. 66(5 Suppl 3):S61-6. 
27. Dickens T. The World Medicines Situation 2011-Procurement of Medicines. 
World Health Organization. 2011.  Available from: 
http://apps.who.int/medicinedocs/documents/s18769en/s18769en.pdf. 
Accessed 5 February 2016. 
28. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine Prices, 
Availability, and Affordability in 36 Developing and Middle-Income Countries: 
A Secondary Analysis Lancet. 2009. 373(9664):632. 
Background to this Thesis 
 
17 
 
29. Harper I, Brhlikova P, Subedi MS, Bhattarai S, Basu S, Gupta AD, et al. Drug 
Procurement in Nepal. 2007.  Available from: 
http://www.csas.ed.ac.uk/__data/assets/pdf_file/0009/38826/DrugProcuremen
tNepal.pdf. Accessed 3 February 2016. 
30. World Health Organization. Practical Guidelines on Pharmaceutical 
Procurement for Countries with Small Procurement Agencies. WHO Regional 
Office for the Western Pacific. 2002.  Available from: 
http://apps.who.int/medicinedocs/pdf/h2999e/h2999e.pdf. Accessed 6 
February 2016. 
31. Government of Nepal, Ministry of Health and Population. Public Procurement 
Guidelines. Government of Nepal, Ministry of Health and Population. 2009.  
Available from: http://mohp.gov.np/index.php/publication-1/guideline. 
Accessed 3 February 2016. 
32. Public Procurement Act 2007, Act Number 36 (2007). Government of Nepal. 
33. Government of Nepal. National Medicines Policy 2007. 2007.  Available from: 
http://www.mohp.gov.np/images/pdf/policy/National%20Medicine%20Policy.p
df. Accessed 5 February 2016. 
 
Chapter 1:  Literature Review	
 
18 
 
 
 
Chapter 1 
Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1:  Literature Review	
 
19 
 
Chapter 1:  Literature Review 
Medicine Procurement in hospital pharmacies through the lens of the Basel 
Statements: Lessons for Nepal 
1.1. Background 
Pharmacy is an integral part of healthcare in health institutions. Pharmacists are 
responsible for managing medicines and related health processes to optimize 
outcomes and enhance safety and quality of health services provided to patients 
Hospital pharmacy is a specialized area of pharmacy practice, described as  the  
“practice of selecting, manufacturing, managing, and dispensing medicines and 
medical devices, and advising healthcare professionals and patients on the safe, 
effective and efficient use of medicines” [1]. Hospital pharmacy is responsible for 
ensuring the 7 “rights” of medicine use for patients: the right patient, right dose, right 
route, right time, right drug with the right information and documentation [1].  
Hospital pharmacy practice has evolved from traditional product-centred practice 
models to contemporary patient-oriented models of services [2, 3]. In the early 1900s 
up until the 1950s, the pharmacy profession was solely focused on medicine 
production, compounding and dispensing. The first substantial change in practice 
came in the mid-1960s when the concept of patient-oriented clinical pharmacy 
services was introduced [3]. There was gradual progression, with academic curricula 
being revised to include clinical pharmacy and providing clinical training to pharmacy 
students. Pharmacist were being considered as drug experts, and there was 
adoption of multidisciplinary collaboration in patient services [2, 3]. It was the early 
1990s when the concept of pharmaceutical care was introduced which emphasised 
the role of pharmacists in rationalising drug therapy [3].  
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Some major advancement also took place throughout the last decade with adoption 
of the concept of personalized medicine, evidence-based decision making 
processes, as well as advanced and specialized education programs [2]. 
Contemporary hospital pharmacy practice in many developed countries is now 
focused on activities such as patient care services, promotion of rational use of 
medications, individualized drug therapy, specialty pharmacy practice, drug-use 
evaluation, and cost-effective analysis [2, 3]. In addition to this, collaborative or 
supplementary prescribing models are flourishing globally and already in practice in 
countries like Canada, United Kingdom (UK) and United States of America (USA) [2]. 
This increasingly complex and diverse nature of hospital pharmacies’ and 
pharmacists’ roles in the health-care system requires established, effective 
standards of services and practice objectives [4].   
Many countries have developed their own national guidelines for various aspects of 
healthcare services and professional practices. For instance, the United States of 
America has American Society of Health-System Pharmacists (ASHP) guidelines [5], 
Australia follows The Society of Hospital Pharmacists of Australia (SHPA) practice 
standards [6], and Europe has the European Association of Hospital Pharmacists 
(EAHP) guidelines [7]. Some developing countries have adapted the FIP-WHO Good 
Pharmacy Practice guidelines to formulate national guidelines to suit their country’s 
health needs in pharmacy. For example, Nepal has adapted FIP-WHO guidelines to 
formulate the National Good Pharmacy Practice Guidelines [8]. The government of 
Nepal has also published Hospital Pharmacy Directives 2013 [9]. 
Doloresco and Vermeulen (2009) conducted a global survey exploring the status of 
hospital pharmacy practice around the world and discovered the existence of 
traditional product-oriented practice models in many countries [10]. Despite the fact 
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that present day hospital pharmacy practice have progressed exclusively in some 
countries, hospital pharmacy in many countries, especially developing and low and 
middle-income countries still follow traditional medicine distribution practices, and 
are still struggling to establish basic clinical practice [11, 12]. For instance, Australia, 
a developed country [13], is advancing clinical pharmacy practices and is practising 
patient-centred specialty pharmacy practices [14, 15] whereas Nepal, a developing 
country [16], still has not progressed from out-dated product-centred pharmacy 
practice models [17, 18]. Therefore, there is a need for adoption of global standards 
based on essential elements of hospital pharmacy practice, in order to improve and 
standardise the pharmacy profession globally,  and achieve professional goals, 
societal expectations and patient care goals [11, 12]. 
With the objective of developing global consensus statements about the 
advancement of hospital pharmacy practice, the ‘Global Conference on the Future of 
Hospital Pharmacy’ was held by the Hospital Pharmacy Section of International 
Pharmaceutical Federation (FIP) in Basel, Switzerland in 2008 [10, 19, 20]. This 
global conference resulted in the development of the first set of international 
consensus statements named the Basel Statements [20], which were based on 
mutual agreement by representatives of hospital pharmacists from around the world. 
These Basel Statements consisted of 75 statements under six key elements of 
hospital pharmacy practice [20], and have been considered as valuable guidelines 
for standardizing hospital pharmacy practice around the globe [21, 22]. Medicine 
procurement is one of the six themes included [12] [20]: 
1. Medicines procurement 
2. Influences on prescribing 
3. Preparation and delivery of medicines 
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4. Administration of medicines 
5. Monitoring of medicines 
6. Human resources and training 
According to the Basel Statements 2008, the “Procurement” theme consists of nine 
statements (Table 2) [20]. 
Table 2: Procurement Guidelines of the Basel Statements 2008 
Statement 
Number 
Statements 
17 The procurement process must be transparent, professional, and ethical to 
promote equity and access and to ensure accountability to relevant 
governing and legal entities.  
18 Procurement should be guided by the principle of procuring for safety. 
19 Procurement of pharmaceuticals is a complex process that requires 
pharmacist control and technically competent staff. 
20 Operational principles for good procurement practice should be regularly 
reviewed and procurement models adapted to fit different settings and 
emerging needs in the most appropriate and cost effective way. 
21 Procurement must be supported by strong quality assurance principles to 
ensure that poor quality medicines are not procured or allowed into the 
system. Proper storage to ensure maintenance of quality in the whole 
supply pipeline is mandatory 
22 Procurement should not occur in isolation, but rather be informed by the 
formulary selection process.  
23 Good procurement must be supported by a reliable information system that 
provides accurate, timely, and accessible information 
24 A formal mechanism must be in place for pharmacists to request designated 
funds to procure medicines for their patients.  
25 Each pharmacy should have contingency plans for medicines shortages 
and purchases in emergencies. 
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The Basel Statements 2008 were revised in September 2014 and published in 2015 
[23]. The current version, the Basel Statements 2015, are comprised of 65 
statements, instead of 75 statements in the first version, however the statements are 
still organised under the same six themes. The procurement guidelines of the 
revised Basel Statements 2015 have been tabulated as below (Table 3) [23].  
Table 3: Procurement Guidelines of the Basel Statements 2015 
Statement 
Number 
Statements 
20 Hospital pharmacists should be involved in the complex process of 
procurement of medicines and health products, promoting equity and 
access. They should ensure transparent procurement processes are in 
place in line with best practice and national legislation, are free from conflict 
of interest, and are based on the principles of safety, quality and efficacy. 
21 Procurement practices must be supported by strong quality assurance 
principles, regularly reviewed and adapted to fit different settings and 
emerging needs in the most appropriate and cost effective way. 
22 Procurement should not occur in isolation, but rather be guided by the 
formulary selection process. This includes the procurement of standard 
concentrations of high-risk medicines including electrolytes. 
23 Procurement must be supported by a reliable information system that 
provides accurate, timely, and accessible information. 
 
Whilst the revised version of Procurement Statements of the Basel Statements 2015 
[23] consists of only four statements, the sentiment of procurement practices has 
remained unchanged. Some statements have remained in their entirety, whilst a few 
similar statements have been merged and few statements have been shifted into the 
overarching and governance statements section, however nothing in the original set 
of statements has been lost [20, 23]. 
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Since the release of the Basel Statements 2008, studies have been conducted 
exploring the implementation of different themes of the Basel Statements and 
alignment of country’s national guidelines with the Basel Statements [21, 24-30]. 
Although a couple of studies assessed compliance of hospital pharmacy practice 
[30] and national guidelines [29] with the Basel Statements, most research has 
focused on exploring clinical pharmacy services, formulary systems, and other 
medicine-use related matters pertaining to Influences on Prescribing theme (theme 
2) of the Basel Statements [21, 24-28]. Research has been conducted in the 
Western Pacific region, China, Uganada and Canada only [21, 24-30]. However, to 
date no studies have been conducted to explore the implementation of the Basel 
Statements in South Asia.  
As medicines are the primary vehicle for medical intervention in the modern era, 
providing access to medicines to patient from all backgrounds is an important issue 
for Nepal. Moreover, hospital pharmacy practice of Nepal is in its infancy, still in the 
medicine distribution model [17, 18]. Therefore, for conducting research in countries 
like Nepal, starting with the basic, yet very crucial theme of “Procurement” from the 
Basel Statements is both practical and relevant.  A few reports about procurement of 
a few selected essential medicines purchased by government for free distribution in 
governmental organizations have been published [31-33], but they do not mention 
procurement procedures for all types of medicines and health institutions. Therefore, 
we aimed to explore procurement practice in hospital pharmacy in Nepal with 
reference to the Basel Statements. 
Since the revised version was published late in 2015 after this research had 
commenced, nine statements from the first version, the Basel Statements 2008 
(Table 2), have been referred to throughout this literature review and thesis. The 
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term Basel Statements used in this literature review and throughout the thesis refers 
to the first version, the Basel Statements 2008. 
1.2. Objective 
The objective of this literature review was to explore literature about procurement in 
hospital pharmacy based on the Basel Statements that could pose as beneficial 
information for improving procurement systems in Nepal. 
1.3. Method 
A narrative literature review was conducted initially to gather relevant information 
and ideas. The literature search was conducted using online databases including 
“Medline via OvidSP”, “PubMed”, “International Pharmaceutical Abstracts via 
OvidSP” and “Cinahl via Ebsco” using the keywords “procurement”, “purchasing”, 
“medicines”, “drugs”, “pharmaceuticals”, “hospital/hospitals”, “Basel statements”, 
“hospital pharmacy practice”, “pharmacy practice”, “transparency”, “corruption”, 
“quality”, “hospital formulary”, “medicines formulary”, “formulary system”, “medicines 
selection”, “drug selection”, “cost-effective”, “cost control”, “medicines safety”, “drug 
safety”, “pharmacists”, “supervision”, “role of pharmacists”, “pharmacy and 
therapeutics committee”, “medicines shortage”, “hospital funding”, “hospital 
expenditure”, “information” and “information system” under the time frame of 2000-
current. 
Bibliographies of articles were also hand searched to find additional relevant articles. 
The website of the World Health Organization (WHO) was searched for gathering 
relevant health statistics and guidelines on pharmacy practice and procurement. 
Websites of the International Pharmaceutical Federation (FIP), American Society of 
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Health-System Pharmacists (ASHP) and European Association of Hospital 
Pharmacists (EAHP) were searched for identification of different guidelines on 
various aspects of hospital pharmacy practice and procurement. Websites of the 
Department of Drug Administration and Ministry of Health of Nepal were browsed for 
statistical, financial and regulatory information and guidelines.  
References from both developing and developed countries were reviewed and 
discussed within the framework of each of the 9 Basel Statements 2008 on 
Procurement. 
1.4. Results 
Pertinent papers that were related to each of the procurement statements of the 
Basel Statements 2008 are referred to under each section.  
1.4.1 “The procurement process must be transparent, professional, and 
ethical to promote equity and access and to ensure accountability to 
relevant governing and legal entities.”  
Pharmaceutical procurement is very susceptible to unethical practices and a study 
has shown that transparency, professionalism and equity are some of the major 
concerning issues of key stakeholders for procurement in healthcare settings [34]. 
Although a global problem, multiple predisposing factors, such as having a weak 
regulatory authority, lack of regulation enforcement, low staff remuneration, poor 
procedures, and inadequate payment practices, place developing countries at higher 
risk of corruption [34]. Lack of transparency can have negative health and economic 
consequences [35] and can have greater impact on poor people because they can 
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neither afford these consequences nor opt for any other alternatives, making them 
deprived of access to medicines [36].  
Medicines selection processes can be influenced by marketing strategies of 
pharmaceutical industries that sometimes manipulate scientific evidence in favor of 
newer, more expensive, on-patent drugs [37]. Such influential practices are common 
in developing countries such as India [38] and China [28], and have also been 
observed in Nepalese hospitals [39]. However, pharmaceutical companies can try to 
influence physicians practicing in developed countries like United States of America 
(USA) to add medicines onto the formulary [40]. To manage such influential 
practices, countries like USA and Australia have developed specific codes of 
conduct for this purpose [41-45]. Moreover, pharmaceutical companies of these 
countries are attempting to avoid unethical practices by following their own internal 
code of conduct [43, 46] that require them to disclose details of promotional 
activities. The Department of Drug Administration of Nepal has formulated 
“Guidelines on Ethical Promotion of Medicine” [47] but these are reportedly yet to be 
fully enforced. Nepal Medical Council has developed the Code of Medical Ethics [48] 
for promoting ethical practice but has failed to cover ethical issues between 
healthcare professionals and pharmaceutical companies. Nepalese pharmaceutical 
companies and regulatory authorities could develop similar codes to further promote 
ethical medicine use and relationships between pharmaceutical companies and 
decision-makers. Nepal can also benefit from international codes and ethical 
guidelines [49, 50] while amending their existing codes and guidelines.  WHO further 
suggested that there should be provision for declaration of a conflict of interest by 
members of P&T Committees and tender committees to minimize opportunities for 
corruption, favouritism or political influence [35].  
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Garuba et al. conducted a study to explore perspective of policy makers on 
transparency in Nigerian public pharmaceutical procurement and reported that 
Nigeria, a developing country like Nepal, has adopted competitive procurement 
procedures, unbiased tender processes and well defined tender committees. 
However, lack of conflict of interest guidelines and public availability of audit results 
were reported to increase vulnerability to corruption in the public procurement of 
Nigeria [51]. Nepal, similar to other developing countries, is also extremely 
vulnerable to corruption [52]. 
WHO has published an assessment instrument for measuring transparency that 
provides a description about the rationale for assessment, assessment criteria and 
scoring [35]. A few proven effective methods proposed include: choosing transparent 
procurement methods that are open and fair, having written procurement guidelines, 
dividing key procurement functions different individuals or committees to avoid 
favouritism and bias, having public dissemination of information (especially of tender 
process and results), having an appeals system, and making sure regular auditing 
and monitoring occur [35, 53]. Ombaka (2009) has outlined that establishing good 
incentive structures may foster ethical behavior [34]. Transparency and corruption-
free procurement practices are essential to gain trust and to maintain mutual 
relationships between implementers and governance organizations [34].  
1.4.2 “Procurement should be guided by the principle of procuring for 
safety.” 
Access to safe medicines is considered a fundamental right of patients [54]. Patient 
safety is therefore a major priority of any health institution, and medicines should be 
procured based on their proven safety and efficacy [35] [34]. A survey by WHO in 
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2005 showed that the majority (63%) of counterfeit medicines came from East Asian 
countries with India (a neighboring country to Nepal) being the leader of counterfeit 
medicines production (35%) [55]. Developing and low-income countries like Nepal, 
which rely on other countries (India, in case of Nepal) for many life-saving and 
essential medicines, and active pharmaceuticals required for medicine production, 
are more susceptible to the introduction of counterfeit and substandard medicines 
because of weak regulatory policies, which can pose serious threats to patient’s 
health [56]. Developed countries like Australia and United States of America (USA) 
have been prioritizing safety in their practices, policies and regulatory procedures 
[54, 57-59]. WHO have published guidelines for developing strategies to prevent 
entry of counterfeit and substandard medicines [60] which can be useful for 
developing countries like Nepal. It has been stated in a literature review by Ombaka 
in 2009, that there should be written procurement procedures with description of 
criteria for selection of medicines that can promote safe practices, strategies for 
decreasing medication errors associated with labelling and packaging, and criteria 
for risk assessment [34]. National Medicine Policy 2007 of Nepal advocates for 
quality of medicines, but safety issues have not yet been given adequate attention 
[61]. Risk assessment tools should be developed and used for suppliers with 
unknown or poor histories and for procurement of new generic products, problematic 
products, parallel import products, products requiring specialized labelling such as 
injectable and products in high-risk therapeutic categories like anticoagulants [34].  
1.4.3. “Procurement of pharmaceuticals is a complex process that requires 
pharmacist control and technically competent staff.”  
Pharmaceutical procurement is a multi-disciplinary process requiring medical, 
pharmaceutical, managerial, financial and sometimes even political expertise [62]. 
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Personnel involved in the procurement process should be competent to ensure the 
availability of acceptable quality medicines at the lowest possible price in a timely 
and appropriate manner [34].  The staff involved in the process should possess good 
communication skills and knowledge of medicines inventory and consumption [62]. 
WHO recommended the presence of at least one pharmacist in a senior position 
overseeing the process, as well as pharmacists with expertise in different aspects of 
the pharmaceutical procurement throughout the supply chain [53]. A practical ASHP 
guideline on P&T Committees and the Formulary Systems [63] and a WHO 
guidelines titled “Drug and Therapeutics Committees-A Practical Guide” (2003) [64] 
have highlighted the role of pharmacists in medicines selection while procuring 
medicines. Nepal’s National Good Pharmacy Practice guidelines also state the 
involvement and supervision of pharmacists in the  procurement process [8]. The 
involvement of clinical pharmacologists, pharmacoeconomics and 
pharmacoepidemiology experts can also be beneficial in cost-effective analysis and 
medicines selection [65].  
1.4.4. “Operational principles for good procurement practice should be 
regularly reviewed and procurement models adapted to fit different 
settings and emerging needs in the most appropriate and cost effective 
way.” 
In order to make the procurement process easier, simpler and effective, several 
operating principles and guidelines have been published by different international 
organizations. One of the best known is the WHO’s “Operational Principles of Good 
Pharmaceutical Procurement” [53] which can be adapted by individual governments 
organizations to develop their own national and internal procurement procedures to 
achieve optimal outcomes from the procurement process. The operational principles 
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should also provide guidance for selecting the most cost-effective medicines of 
appropriate quality to treat common diseases prevalent within the health institution. 
These principles tackle and minimize possible procurement-related problems, help 
develop improvement plans, pre- and post-qualification procedures, continuous 
monitoring of system and suppliers, and management of procurement and delivery 
[34, 53]. 
The Government of Nepal has developed the Public Procurement Act 2007 [66] and 
Public Procurement Regulations 2007 [67] to regulate public procurement in Nepal. 
In order to assist public procurement procedures, Nepal has also published the 
Public Procurement Guidelines [68] that could be utilized by all health organizations. 
Similarly public procurement in Australia must be conducted in Australian public 
hospitals by utilizing their own hospital policies in accordance to the Commonwealth 
Procurement Rules [69] and their state and national policies. 
Clinical and pharmaceutical advancements and innovations around the world are 
causing incremental increases in medicine and total health expenditure [70]. 
According to Milovanovic et.al., 2004, there is therefore an urgent need to control 
health expenditure through the development and implementation of national 
medicines policies, with a focus on procurement [65]. Decisions should be based 
initially on considerations of clinical effectiveness and then on cost-effectiveness 
[71]. Cost containment is even more important in developing countries like Nepal, 
which have limited resources and a lack of medicines financing facilities, and where 
the general public is required to pay completely by themselves [32, 62].  
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Purchasing medicines based on a formulary list is one of the methods to control 
medicines expenditure [72]. Two approaches have been proposed to control 
medicines expenditure [73]: 
1. Supply-side management- focuses on negotiations and includes price control, 
profit control, pooled procurement, rebates, reference pricing, expenditure 
ceilings 
2. Demand-side management- focuses on the management of medicines use by 
prescribers and patients and includes educational campaigns, prescribing 
guidelines, patient co-payments, switching prescription medicines to over-the-
counter medicines, promoting the use of generics, budget decentralization, and 
regulating medicines promotion.  
European countries have also developed similar price control policies and have been 
successful at controlling costs of medicines [74]. Australia has the Pharmaceutical 
Benefits Scheme which provides medicines to the public at government-subsidized 
prices [75]. According to Barraclough and Clark (2012), pooling volumes of 
medicines from each unit, institution, region or country to create a single large 
volume,  has been reported to attract more suppliers and provide more competitive 
prices [62].  Several organizations like United Nations Children's Fund (UNICEF), 
United Nations Development Programme (UNDP), and Stop TB Global Drug Facility, 
and countries like New Zealand and India have utilized pooled procurement to 
control medicine expenditure and increase availability of medicines [62, 73, 76]. 
Nepal also utilizes a pooled procurement system, but only for purchasing some 
essential medicines that are freely distributed for public health institutions [33]. 
Additionally, group contracting or contractual agreements have been suggested as 
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useful add-ons in pooled procurement. These group contracting agreements follow 
centralized tendering systems (i.e. tender conducted and the best price negotiated 
centrally by the central governing body of group/organization/country on behalf of all 
associated member organizations), but allow decentralized purchasing by individual 
organizations in a group or parent organization or country [77, 78]. Various 
international organizations like United Nations Children’s’ Fund, United Nations 
Population Fund and Global Fund, and countries like the United States in their 
Department of Veterans' Affairs and Department of Defense have also benefitted 
from these strategies [78]. Similar strategies have also been recommended for low 
and middle-income countries like Nepal [79]. Nepal could also utilize ASHP 
guidelines on cost management which provides guidance on budget planning, 
maximizing resource use, and managing procurement and inventories [70].Good 
price negotiation is achievable with the support of local and global price information 
and market surveillance [34]. Furthermore, transparency in the tender process can 
attract suppliers which can increase competition, giving the lowest possible price. 
Reliable payment mechanism and prompt payment methods can also minimize 
prices [62].  
1.4.5. “Procurement must be supported by strong quality assurance principles 
to ensure that poor quality medicines are not procured or allowed into 
the system. Proper storage to ensure maintenance of quality in the 
whole supply pipeline is mandatory.”  
The quality of medicines is one of the key components of pharmaceutical 
procurement because of increasing availability of counterfeit, substandard and 
contaminated medicines on the market that have the potential to pose serious health 
threats [62]. Problems with counterfeit medicines are more common in developing 
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countries because of their weak regulatory policies and enforcement capacities as 
compared to developed countries with strong enforcement of regulatory policies and 
more transparent supply chains [56]. For instance, developed countries like Australia 
have well-developed regulatory frameworks such as the Therapeutic Goods 
Australia (TGA), for ensuring quality of medicines, and preventing entry of counterfeit 
medicines [80]. In comparison, 25-50% of medicines in developing countries are 
reportedly counterfeit [81]. Counterfeit and substandard medicines can have serious 
health and economic consequences, that may complicate the work of healthcare 
providers and policy makers in correcting and preventing such problems [56]. The 
loss of economy, quality of life and work productivity can create a never-ending 
vicious cycle of poverty in the developing world [81]. Nepal shares an open border 
with India, where availability and production of counterfeit and substandard medicine 
are high [55]. Since Nepal heavily relies on India for medicines, especially life-saving 
medicines, and raw materials for local pharmaceutical manufacturing, Nepal is very 
susceptible to introduction of counterfeit and substandard medicines. It is therefore 
necessary for health organizations to develop and implement their own internal 
quality-assurance systems based on national or international guidelines and 
evaluate the quality of products and suppliers before, during and after purchasing. A 
model of quality assurance system developed by the WHO [82]  and a guide 
published by the Management Sciences for Health [62] could be utilized to develop 
and implement internal quality-assurance systems. Although both prequalification 
and post-qualification have been used for analysis of suppliers of medicines, 
prequalification is generally preferred and considered to be more effective [62].  An 
effective procurement procedure should assure that procured medicines are of the 
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specified quality and should monitor and maintain the quality throughout the 
distribution chain [62].  
Four components for making a quality assurance system effective are: selection of 
reliable suppliers, use of existing international mechanisms, established programmes 
for product defect reporting and use of targeted quality control testing [53]. Quality of 
products can be examined by various physical and qualitative tests which can be 
undertaken in a hospital’s own laboratory or in coordination with other independent 
or national quality control laboratories [34]. Moreover, inexpensive and easy to use 
quality control test kits are also available [83].  
In an attempt to combat counterfeiting globally, the WHO has also established 
guidelines for the development of measures to combat counterfeit drugs [60], which 
could be a useful resource for Nepal.  Purchasing medicines from prequalified 
suppliers is another recommended way of avoiding counterfeit and substandard 
medicines. The WHO has a prequalification of medicines programme to review 
quality of medicines [84] and Nepal can utilize this list of WHO prequalified suppliers 
to minimize the risk of purchasing poor quality medicines, especially when 
purchasing from countries with high rate of counterfeit medicine production like India.  
Storage is an important aspect of total drug control, and proper control has to be 
made in and throughout the institution [85]. Proper storage of medicines is essential 
to maintain integrity of packaging which preserves quality of medicines and to avoid 
contamination, deterioration, pest infestation, theft and losses. Medicines should be 
stored in environmentally controlled storage areas that have adequate temperature, 
sufficient lighting, humidity control, clean and cold storage facilities, and proper 
ventilation, to ensure integrity of medicines [85, 86]. Storage areas should be 
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secured and designed to restrict access only to designated and authorized persons 
[87]. Medicines should be arranged in a systematic way to avoid errors, especially 
for lookalike and sound-alike medicines and medicines with identical packaging [87]. 
Storage of hazardous, flammable and poisonous medicines should be given special 
considerations. Hospitals should establish a proper method for identifying and 
managing expired, deteriorated, recalled or obsolete medicines and supplies [85]. 
1.4.6. “Procurement should not occur in isolation, but rather be informed by 
the formulary selection process.”  
Poor selection of medicines is considered one of the important factors for problems 
associated with medicines use [64]. Furthermore, complexity of the prescribing 
process can also lead to irrational prescribing practices.  Data from the WHO shows 
that more than half of all medicines prescribed, dispensed or sold are inappropriate. 
One of the effective and recommended solutions is to develop formulary system to 
restrict medication choices, promote rational use of medicines and ensure effective 
medicines management [24]. Moreover, formulary processes involve different 
stakeholders in decision making, which avoids influences by special interests and 
contributes to professionalism, accountability and avoidance of conflicts of interest 
[35].   
The formulary system is a continuous process of selecting evidence-based cost-
effective medicines in health care organizations with the aim of achieving the best 
therapeutic outcomes with minimal adverse effects. This system works on 
establishing policies on use of medicine and related products, treatment protocols, 
and selecting cost-effective and appropriate medicine and treatment that are best 
suited for targeted population. A formulary consists of a list of medicines and 
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associated products, medicine use policies, important drug information, decision-
support tools, and organizational guidelines. This formulary system could be utilized 
by hospitals, acute and chronic care facilities, home care settings, and health service 
payers like Medicaid, Medicare and insurance companies. [88]. Countries like the 
USA, Europe and Australia adopt the formulary process for selecting medicines [24]. 
Hospital Pharmacy Directives 2013 [9] of Nepal also recommend formulary selection 
process. 
Pharmacy and Therapeutics (P&T) Committees are the responsible bodies for the 
development of formulary list through evidence-based selection of medicines and 
standard treatment guidelines [64]. Hospital Pharmacy Directives of Nepal define the 
role of the P&T Committees in selection of medicines for procurement in consultation 
with each committee of the procurement system [9]. P&T Committees’ work and 
members should be free of influential strategies like inappropriate drug 
advertisements, promotional activities, personal financial interests or any kind of 
beneficiaries [64]. The WHO and ASHP have published guidelines for establishing 
P&T Committee and formulary system [64, 88]. The WHO has published model 
formularies [89] which can be a useful resource for hospital pharmacists of Nepal. 
Similarly, the government of Nepal has published Nepalese National Formulary [90] 
which can be used by hospitals to develop their own formulary based on standard 
treatment guidelines or protocols best suited for use in the hospital and local 
populations [64].  
Alternatively, the national list of essential medicines could be utilized for medicine 
selection and guide public medicine procurement process. The national list of 
essential medicines is the list of essential medicines developed by the country on the 
basis of national health and drug policies, patterns and prevalence of diseases, 
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pharmaco-economic evaluation, and quality and levels of service provided. This list 
could also be utilized for medicine donations, local pharmaceutical manufacturing, 
and medicine reimbursement scheme [91]. Hospital pharmacies of Nepal could 
follow the National List of Essential Medicines [92] developed by the government of 
Nepal. 
The criteria for drug selection should include: cost-effectiveness, affordability, 
disease prevalence, safety, efficacy and quality. Appropriate selection can finally 
result in cost containment, improved access to essential medicines and improved 
quality of care.  
1.4.7. “Good procurement must be supported by a reliable information system 
that provides accurate, timely, and accessible information.”  
Information is the lifeblood of an effective procurement system. Accurate and timely 
information exchange within the institution as well as between suppliers and the 
institution can reduce inaccuracies in cost and procurement [34]. A management 
information system should be available for the procurement office and its clients to 
monitor and track the status and different aspects of medicine procurement process 
and problems encountered during the process. The information system must be 
available for monitoring  the performance of health system, financial management, 
quality assurance system and overall pharmacy management [35, 62].  
The information of the hospital system can be documented manually or 
electronically, but electronic systems are preferred as they minimize chances of 
human error [34]. Reliable information systems that provide updated information on 
reference prices can provide basis for price negotiation to achieve favorable prices 
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[34]. Dissemination of information is also important for maintaining transparency in 
the procurement process [35] and managing medicines shortage at hospitals [93].  
Countries like USA and Australia circulate information about medicines safety and 
shortages through their websites of US FDA [94, 95]  and TGA [96, 97] respectively. 
Nepal can also develop similar online information systems for providing information 
about medicines and medicine shortages that would help in managing medicine 
procurement in hospitals.  
1.4.8. “A formal mechanism must be in place for pharmacists to request 
designated funds to procure medicines for their patients.”  
Financing is the driving force of the procurement process and the appropriate 
financing mechanism should be chosen to ensure availability and resourceful use of 
funds [34]. Different financing mechanisms are available that include: public 
financing, health insurance, user fees, donor financing, and development loans [34]. 
Prompt and reliable payment can attract suppliers and provide competitive prices 
and good service from suppliers. Procurement may be funded differently depending 
on type of health institutions [62].  
Public procurement in Australia is funded by the Australian government, whereas in 
Nepal it is funded partially by the government and donor organizations (only for a few 
freely distributed essential medicines) and the remainder is based on the sales of 
medicines or the budget of healthcare organizations [9, 98]. In addition to this, 
medicines approved for use in Nepal and listed in the national EMLs could be 
donated by donor agencies in accordance to the Guidelines for Drug Donation and 
with import approval from the Department of Drug Administration of Nepal. Normally, 
medicine can be donated to either legally registered health institutions or Ministry of 
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Health and Population of Nepal. However, during emergencies, medicines donations 
can occur only through Ministry of Health and Population of Nepal [68]. 
1.4.9. “Each pharmacy should have contingency plans for medicines 
shortages and purchases in emergencies.” 
Medicines shortages can have serious implications on healthcare delivery, economy 
of the hospital and patient’s health [93]. There are many contributing factors that can 
cause medicines shortages, but the major causes that can arise from within 
healthcare institutions are: poor inventory management, lack of information flow and 
communication, and change in clinical practice.  
Due to the unpredictable and unavoidable nature of medicines shortages, strategic 
planning should be developed for its management. Existence of contingency plans is 
of utmost importance in Nepal because of its difficult geography, and susceptibility to 
natural disasters, health epidemics and political instability that are likely to trigger 
medicine shortages [99-102]. 
ASHP has recommended a three-phased approach for managing medicines 
shortages: 1. identification and assessment of the shortage and its impact, 2. 
preparation for alternatives and managing shortages, and 3. contingency planning to 
deal with medicines shortages [93].  Healthcare institutions should establish 
guidelines for dealing with unavailability of critical or essential medicines, as well as 
rationalizing the distribution of available medicines ethically. Hospitals should 
develop strong policies for purchasing medicines of unassured quality and safety 
from compounding sources and non-traditional sources so that actions can be taken 
against any possible problems [93, 103]. 
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While implementing contingency plans, ASHP has recommended that hospital 
pharmacists or concerned departments should also evaluate economic aspects, 
because alternative medicines and sources can increase the cost of treatment [104]. 
Moreover,  a reliable information management system similar to those utilized by 
countries like USA [94] and Australia [97] that can facilitate communication and 
circulation of information about the status of medicines shortage among all 
concerned and affected departments, clinicians and patients is very essential [104]. 
This information sharing process could be made more effective by making it 
mandatory, as in the USA [105]. Regular reporting on key procurement performance 
indicators and auditing, are also equally important for planning and managing 
procurement [53].  
1.5. Discussion 
Medicines procurement is an important element of health care facilities that requires 
expertise from different disciplines. However, not all aspects of medicines 
procurement are well reported in the literature. Some aspects like transparency, 
corruption, counterfeit products, cost containment, medicines quality and medicines 
selection have been studied extensively, whereas other aspects such as quality 
assurance systems, storage, funding mechanisms and information systems were 
found to be poorly studied and limited to policies and guidelines. It was also found 
that some elements like safety and information systems were studied from the 
perspective of medicines distribution and administration rather than procurement. 
Corruption and unethical practices were considered to have large influences on the 
procurement process, especially in developing countries, due to weak regulatory 
policies and enforcement capacities, as compared to developed countries with 
Chapter 1:  Literature Review	
 
42 
 
strong regulatory enforcements in place. Division of different procurement functions 
was found to minimize the corruption, bias and favouritism in the procurement 
process.  
There is evidence that an open and transparent procurement method is more 
effective for procuring the right medicines, with recognizable standards of quality at 
the most competitive prices. Medicines selection processes have been found to be 
influenced by marketing strategies of big pharmaceutical companies in both 
developed countries and developing countries. 
Another key issue identified was counterfeiting, especially in Asian countries where 
the majority (63%) of counterfeit products are manufactured. Due to physical 
proximity and porous borders between the two countries, medicine procurement in 
Nepal is highly susceptible to entry of counterfeit medicines produced in India, so 
special emphasis should be placed on ensuring the authenticity of drugs. As such, 
prequalification and post-qualification of medicines and suppliers are very important 
in developing countries where financial resources are limited, and health and 
economic losses from counterfeit and substandard medicines are unaffordable.  
The literature supported the role of pharmacists in the procurement process, 
especially in the selection of medicines. Furthermore, cost containment was 
considered to be an urgent need. Procuring medicines at lowest possible prices is 
important for Nepal where budgets are limited and accessibility of medicines 
depends on proper utilization of available funds. Pooled procurement, group 
contracting strategies, price negotiation, transparency, reliable/ prompt payment 
mechanisms, use of generic medicines and strong market information were found to 
be effective in achieving lowest possible prices.  
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The procurement system should be supported by a reliable information system and 
strong funding mechanisms. Although some funding mechanisms were found to be 
in place, no evidence for use of such information systems in Nepal was found in the 
literature. Therefore, one way Nepal can strengthen its procurement system is by 
establishing a strong information system.  
The management of medicines shortage should be addressed with emphasis on the 
safety and costs of healthcare delivery. However, evidence of such contingency 
plans was not found in Nepal from the literature and guidelines. Nepal could consider 
developing some strategic plans for managing medicines shortages by following the 
three-phased approach of ASHP.  
In summary, this review provided insight into guidelines, influential factors, 
inefficiencies and solutions to different aspects of medicines procurement in 
hospitals, which can be used for strengthening the procurement system in 
developing countries like Nepal where improving availability of medicines is a current 
health need. This review revealed that some aspects of hospital pharmacy in Nepal 
have not been studied at all; for example, information facilities and contingency 
plans. This suggests that there is a need to conduct more thorough and broad 
studies looking at all aspects of medicines procurement at hospital pharmacies in 
Nepal. The governmental regulatory body should also have a system in place to 
publish public reports annually or every few years on the performance of hospital 
pharmacies.   
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Chapter 2: Aim, Method and Rationale of the Study 
As stated in Chapter One, public healthcare expenditure is less than 5% of the total 
healthcare expenditure and availability of medicines in the public sector is poor in the 
majority of developing countries in Asia [1]. About 60-75% of South-East Asian 
countries therefore have to rely on expensive private health institutions for their 
health needs [2]. Availability of medicines in public hospitals is lower than that in 
private hospitals whereas price is 66.3% higher in private hospitals of Nepal [3]. Due 
to poor availability and higher prices of medicines along with lack of universal 
healthcare in many low-income countries, medicines tend to be unaffordable for the 
majority of the population in these countries [4]. The government of Nepal has been 
distributing a selected few essential medicines to the general public through public 
health institutions as part of a free basic health program. However, public 
procurement and availability of essential medicines in public institutions has been 
reported to be poor [5]. Increasing the availability of affordable and quality medicines 
in public health institutions is beneficial in ensuring equitable access of medicines to 
the general public of all backgrounds.  
For these reasons, this study was divided into two parts-1. Medicine Procurement 
in both private and public hospitals of Nepal, 2. Comparison of medicine 
procurement procedures in public hospitals of Nepal and Australia with the aim of 
identifying ways to strengthen public procurement of Nepal. In doing so, 
dissemination of the results of this research could provide strategies that will have 
meaningful impact on medicine access by a wide range of the country’s population. 
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This chapter describes the overall aims and methods of a large study, divided into 
two parts that are reported as manuscripts ready for publication in Chapters three 
and four of this thesis.  
2.1. Aim 
This study aimed to explore the implementation of international hospital pharmacy 
guidelines (FIP Basel Statements 2008) in the context of procurement in hospital 
pharmacies of Nepal and to compare with the current procurement practice in 
hospital pharmacies of Australia.  
2.2. Objectives 
The major objective of this study was to provide insight into current procurement 
practices in Nepalese and Australian hospital pharmacies, highlight facilitators and 
barriers for guideline implementation in current practices, and report good 
procurement procedures. Another objective was to provide evidence-based 
recommendations to improve current practices of Nepal to facilitate equitable access 
to quality and evidence-based safe medicines to the general public of Nepal. 
2.3. Rationale of the Study 
This study was divided into two parts: 1) study of medicine procurement in hospital 
pharmacies of Nepal (Chapter Three), and 2) comparative study of medicine 
procurement in hospital pharmacies of Australia and Nepal (Chapter Four).  
The first part of the study aimed to explore medicine procurement practices in both 
private and public hospitals of Nepal in order to discover facilitators and barriers to 
guideline implementation. Chapter Three therefore describes medicine procurement 
procedures in hospital pharmacies of Nepal, assesses compliance of the 
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procurement guidelines of the Basel Statements, highlights barriers to compliance, 
and finally provides recommendations based on international guidelines and 
experiences from other countries.  
Chapter Four pertains to the second part of the study comparing medicine 
procurement practices in public hospitals of Nepal to Australia, as it was 
hypothesized that Australia, being a more developed country would have stronger 
regulatory and policy frameworks and be better at adopting procurement policy 
guidelines. Therefore, the reason for comparing procurement practices in these two 
diverse countries was to determine if procurement procedures that were thought to 
be better in Australia could be utilized to improve the current procurement practices 
in Nepal. In this part of the study, comparisons were drawn again in the context of 
the international procurement guidelines of the Basel Statements, which were 
developed to promote best procurement practices around the world. 
2.4. Ethics 
This study was approved by the Human Research Ethics Committee at the 
University of Sydney [Project No. 2014/619]. All documents, including Participant 
Consent Form and Interview Protocol were approved by the ethics committee. 
2.5. Method 
2.5.1. Sampling 
Hospital pharmacists or procurement officers at hospital pharmacies of both private 
and public hospitals of Nepal were contacted. In Australia, hospitals pharmacist or 
procurement officers of public hospitals were approached for participation. A passive 
snowballing sample collection technique was used [6]. Involvement in procurement 
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procedures, speaking fluent English or Nepali were the only inclusion criterion for 
participation. Hospital pharmacists or procurement officers working at major 
hospitals of all five regions of Nepal, and public hospitals in six states and two 
territories of Australia, were targeted for inclusion in this study. Hospital pharmacies 
were selected regardless of whether the hospital pharmacy was regulated/ owned by 
the hospital itself or if it was under a private lease agreement to provide medicines to 
the hospital. Sample characteristics are presented in Table 4.  
Table 4: Sample Characteristics  
Sample  Sample  Characteristics/Quantity 
Participants  Hospital Pharmacists or Procurement Officers 
Inclusion Criteria for 
Participants 
Involvement in the procurement process 
Sampling Technique Passive Snow Balling 
Key Contact Points 1. Nepal 
a. The Hospital Pharmacists’ Association of Nepal,  
b. A private company of pharmaceutical products, and  
c. Prominent figures in the profession such as the Vice 
President of the Hospital Section of International 
Pharmaceutical Federation (FIP) for the South East 
Asian Region 
2. Australia 
a. The Society of Hospital Pharmacists of Australia 
b. Academics of author’s institution 
Area Targeted Nepal: 5 regions of Nepal 
Australia: 6 states and 2 territories of Australia 
Area Covered Nepal: 4 major regions of Nepal 
Australia: 4 states and 2 territories of Australia 
Hospitals Nepal: 
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a. Public hospitals including Logistic Management Division, 
Department of Health Services, Ministry of Health and 
Population, Nepal 
b. Private hospitals including International Non-
Governmental Organization (INGO) funded hospitals 
 Australia 
a. Public hospitals 
Number of Sample Australia: 9  
Public hospitals 9 
 Nepal: 53 
 Public Hospitals 12  
Private Hospitals  37 
INGO-funded hospitals 3 
Logistic Management Division, Department of Health 
Services, Ministry of Health and Population, Nepal  
1 
Total Sample for first 
study (Chapter 3) 
53  
Total Sample for 
second study 
(Chapter 4)  
22  
 
 
In Nepal, the Hospital Pharmacists’ Association of Nepal, executives of a private 
pharmaceutical company, and the Vice President for the Hospital Pharmacy Section 
of International Pharmaceutical Federation (FIP) in the South East Asian Region 
assisted in the recruitment process. In Australia, the Society of Hospital Pharmacists 
of Australia and academics at the University of Sydney helped invite prospective 
participants. 
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2.5.2.  Data Collection and Analysis 
Data were collected using a standard semi-structured interview protocol (Appendix 1; 
Page 173). The procurement statements from the Basel Statements (Table 2) [7] 
were used as a benchmark, for developing interview questions. Additionally, two 
other  assessment tools “Measuring Transparency in the Public Pharmaceutical 
Sector” [8] and “Operational Principles for Good Pharmaceutical Procurement” [9] 
published by World Health Organization (WHO) were also used in conjunction to 
formulate more specific questions. Interviews in Australia and Nepal were 
conducted using the same interview protocol. English was the language used for 
conducting interviews in Australia, whereas participants could choose either English 
or Nepali language for their interviews. All participants consented for interviews in 
written form. All interviews were audio-recorded and then transcribed verbatim. A 
bilingual native Nepali speaker translated Nepali transcripts into English. Data 
collection continued until “saturation”, that is when no new concepts emerged [10]. 
Table 2: Procurement Guidelines of the Basel Statements 2008 
Statement 
Number 
Statements 
17 The procurement process must be transparent, professional, and 
ethical to promote equity and access and to ensure accountability to 
relevant governing and legal entities.  
18 Procurement should be guided by the principle of procuring for safety. 
19 Procurement of pharmaceuticals is a complex process that requires 
pharmacist control and technically competent staff. 
20 Operational principles for good procurement practice should be 
regularly reviewed and procurement models adapted to fit different 
settings and emerging needs in the most appropriate and cost effective 
way. 
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21 Procurement must be supported by strong quality assurance principles 
to ensure that poor quality medicines are not procured or allowed into 
the system. Proper storage to ensure maintenance of quality in the 
whole supply pipeline is mandatory. 
22 Procurement should not occur in isolation, but rather be informed by the 
formulary selection process.  
23 Good procurement must be supported by a reliable information system 
that provides accurate, timely, and accessible information. 
24 A formal mechanism must be in place for pharmacists to request 
designated funds to procure medicines for their patients. 
25 Each pharmacy should have contingency plans for medicines shortages 
and purchases in emergencies. 
 
Data analysis was conducted iteratively, using a framework analysis approach [11] 
based on the procurement themes of the Basel Statements [7], with the assistance 
of NVivo software Version 10 [12]. Data from private and public hospitals of Nepal 
was used to explore medicine procurement practices in Nepal. The comparative 
study was conducted using data from public hospitals of Nepal and Australia to study 
differences and similarities between procurement practices of Nepal and Australia. 
The same dataset from public hospitals of Nepal, which was used for exploring 
medicine practice of Nepal, was re-utilized and new additional data set from 
Australian study was used for the comparative study.  The research team was 
continuously involved throughout the analysis process to achieve consensus. The 
methodology can be summarised as below in Figure 4: 
Chapter 2: Aim, Method and Rationale of the Study	
 
68 
 
 
Figure 4: Methodology of Qualitative Study 
 
 
2.5.2.1. Framework Analysis 
Framework analysis is an analytical approach developed by Ritchie and Spencer in 
the 1980s. This method organises data and develops a matrix based on key themes, 
concepts and categories, making the process systematic and transparent facilitating 
retrieval and tracking of data [11, 13]. This approach can provide cross-case and 
Data Analysis by Framework Analysis method
Data Handling
Transcribing Translation (if necessary)
Data Collection (until saturation of themes)
Interviews using semi-structure 
questionnaire Recording/ Taking notes
Sample Collection
The Society of Hospital Pharmacists of 
Australia (SHPA), Academic Staffs of the 
University of Sydney
Hospital Pharmacists Association of Nepal 
(HosPAN), Executives of a private pharmaceutical 
company, and Vice-President of Hospital Pharmacy 
Section of WHO-SEAR of FIP
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within-case analyses [13]. Framework analysis method consists of five stages which 
are as follows [13]: 
1. Familiarisation  
2. Constructing an initial thematic framework 
3. Indexing and sorting 
4. Reviewing data extracts 
5. Data summary and display [13] 
The framework analysis approach is primarily used for analysing data with 
interwoven and interspersed concepts, and also for data with predetermined 
concepts such as those of semi-structured interviews [13]. It is suitable for data 
covering similar topics or key issues that can generate themes capable of providing 
full description on the phenomenon under investigation [13, 14]. Framework analysis 
can be used for generating pre-selected themes from previous literature, existing 
theories or the specifics of the research questions during data collection (termed 
deductive method). It could also be from the data after data collection (termed 
inductive) depending on the research type [14, 15]. A combined approach can be 
utilized when the research study already has some particular issues to explore and 
aims to discover some unexpected aspects from the interviewees [13].  Since we 
used semi-structured interviews to conduct the study regarding a pre-existing 
concept (the Basel Statements), a pre-defined issue (procurement practices and 
their compliance to the Basel Statements) and also had an aim to discover excellent 
procurement procedures and identify facilitators and barriers, the framework analysis 
approach was considered suitable. 
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Whilst the same dataset from Nepal was used for the studies reported in Chapters 
Three and Four, additional Australian data were added to Chapter Four in order to 
make a comparison, therefore the two chapters have synergistic, yet different 
objectives. 
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Chapter 3: Medicine Procurement in hospital pharmacies of Nepal: A 
qualitative study based on the Basel Statements 
This chapter is presented in the form of a manuscript that has been submitted to a 
peer reviewed journal “PLoS ONE” and is currently under review. 
3.1. Abstract 
3.1.1. Objective 
Accessibility and affordability of evidence-based medicines are issues of global 
concern. For low-income countries like Nepal, it is crucial to have easy and reliable 
access to affordable, good-quality, evidence-based medicines, especially in the 
aftermath of natural or manmade disasters. Availability of affordable and evidence-
based high quality medicines depends on the medicine procurement procedure, 
which makes it an important aspect of healthcare delivery. In this study, we aimed to 
investigate medicine procurement practices in hospital pharmacies of public and 
private hospitals of Nepal within the framework of International Pharmaceutical 
Federation [FIP] hospital pharmacy guidelines “the Basel Statements”.  
3.1.2. Method 
We conducted semi-structured interviews with hospital pharmacists or procurement 
officers in hospital pharmacies of four major regions in Nepal to explore procurement 
practices. Data were collected until saturation of themes, analysed using the 
framework approach, and organised around the statements within the procurement 
theme of the Basel Statements.  
3.1.3. Results 
Interviews conducted with 53 participants revealed that the procurement guidelines 
of the Basel Statements were adopted to a certain extent in hospital pharmacies of 
Nepal. It was found that the majority of hospital pharmacies in Nepal reported using 
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an expensive direct-procurement model for purchasing medicines. Most had no 
formulary and procured medicines solely based on doctors’ prescriptions, which 
were heavily influenced by pharmaceutical companies’ marketing strategies. Whilst 
most procured only registered medicines, a minority reported purchasing 
unregistered medicines through unauthorised supply-chains. And although the 
majority of hospital pharmacies had some contingency plans for managing medicine 
shortages, a few had none.  
3.1.4. Conclusions 
Procurement guidelines of the Basel Statements were thus found to be partially 
adopted; however, there is room for improvement in current procurement practices in 
hospital pharmacies of Nepal. Adoption and regulation of national and international 
policies is recommended for enhancing medicine accessibility, as well as improving 
preparedness for health emergencies during natural disasters and health epidemics.  
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3.2. Introduction 
 A hospital pharmacy is an integral part of healthcare in health institutions and is 
responsible for all medicine-related and management health processes to optimize 
outcomes and enhance the safety and quality of health services provided to patients 
[1]. There is large variation in the nature of services provided at hospital pharmacies 
around the globe, ranging from basic supply to advanced clinical services. However, 
with growing focus on patient-centred care, more complex services have become 
necessary in hospital pharmacies in many countries. In order to enhance hospital 
pharmacy practice globally, standardised guidelines based on essential elements of 
hospital pharmacy practice need to be followed  [2, 3]. 
With the objective of developing global consensus statements for advancement of 
hospital pharmacy practice, the Hospital Pharmacy Section of International 
Pharmaceutical Federation (FIP) developed the first set of international consensus 
statements, named the Basel Statements, in 2008 [4]. The Basel Statements are 75 
statements grouped under six key elements of hospital pharmacy practice, and are 
considered valuable guidelines for standardizing hospital pharmacy practice around 
the globe. Medicine Procurement is one of the six themes covered by the Basel 
Statements [4].  
The procurement theme of the Basel Statements (Table 2) highlights different 
aspects of procurement, such as a) implementation of an appropriate and cost-
effective procurement model with reliable information facilities and necessary funds 
to facilitate transparent and ethical purchasing, b) medicine selection based on 
formulary by adopting strong quality assurance principles, and c) establishment of 
contingency plans for effective management of medicine shortages [4]. 
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Table 2: Procurement guidelines of the Basel Statements 2008 
Statement 
Number 
Statements 
17 The procurement process must be transparent, professional, and ethical 
to promote equity and access and to ensure accountability to relevant 
governing and legal entities.  
18 Procurement should be guided by the principle of procuring for safety. 
19 Procurement of pharmaceuticals is a complex process that requires 
pharmacist control and technically competent staff. 
20 Operational principles for good procurement practice should be regularly 
reviewed and procurement models adapted to fit different settings and 
emerging needs in the most appropriate and cost effective way. 
21 Procurement must be supported by strong quality assurance principles to 
ensure that poor quality medicines are not procured or allowed into the 
system. Proper storage to ensure maintenance of quality in the whole 
supply pipeline is mandatory. 
22 Procurement should not occur in isolation, but rather be informed by the 
formulary selection process.  
23 Good procurement must be supported by a reliable information system 
that provides accurate, timely, and accessible information. 
24 A formal mechanism must be in place for pharmacists to request 
designated funds to procure medicines for their patients. 
25 Each pharmacy should have contingency plans for medicines shortages 
and purchases in emergencies. 
 
Pharmaceutical procurement is a multi-disciplinary process requiring medical, 
pharmaceutical, managerial, financial and often political expertise An effective 
pharmaceutical procurement process should ensure availability of the right drugs in 
the right quantities, at the right time, for the right patients at reasonable prices, and 
at recognizable standards of quality [5]. Pharmaceutical procurement is very 
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susceptible to unethical practices. A study undertaken in 2009 demonstrated that 
transparency, professionalism and equity are some of the major concerning issues 
related to procurement in healthcare settings [6]. Although a global problem, multiple 
predisposing factors such as having a weak regulatory authority, lack of regulation 
enforcement, low staff remuneration, poor procedures and inadequate payment 
practices, place developing countries at higher risk of corruption [6]. According to 
Corruption Measurement Tools of the Transparency International, Nepal is 
vulnerable to corruption with low corruption perceptions index of 31 out of 100 and 
corruption control score of -0.68 (score ranges from -2.5 to 2.5) [7]. Lack of 
transparency can have negative health and economic consequences which can lead 
to loss of credibility and clients’ trust in the hospital services [5]. Moreover, this can 
have greater impact on poorer people, because they can neither afford these 
consequences nor opt for any alternatives, depriving them of access to medicines 
[8].  
Rational selection of medicines is also considered one of the important factors 
associated with medicines use [9]. Data from the World Health Organization (WHO) 
shows that more than half of all medicines prescribed, dispensed or sold are 
inappropriate [10]. Moreover, medicine selection processes have been influenced by 
marketing strategies of pharmaceutical industries that manipulate scientific evidence 
in favor of newer, more expensive, on-patent drugs. For example, pharmaceutical 
companies can even influence physicians practicing in developed countries like 
United States of America (USA) to add medicines onto the formulary [11]. Such 
influential practices have also been seen in Nepalese hospitals [12].  
Clinical and pharmaceutical advancements and innovations around the world are 
causing incremental increases in medicine and total health expenditure [13]. These 
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increases have greater impact in developing countries like Nepal, which have limited 
resources and lack of reimbursement for medicines, resulting in the necessity for the 
general public to pay entirely by themselves [14, 15].  
Additionally, the quality of medicines is one of the key components of pharmaceutical 
procurement because of increasing availability of counterfeit, substandard and 
contaminated medicines on the market, that have the potential to pose serious 
health threats [15]. A survey by WHO showed that the majority (63%) of counterfeit 
medicines came from East Asian countries, with India (which is a neighboring 
country of Nepal) being the leader of counterfeit medicines production (35%) [16]. 
Such problems are more common in developing countries like Nepal because of 
their weak regulatory policies and enforcement capacities as compared to developed 
countries with strong enforcement of regulatory policies and more transparent supply 
chains [17]. Counterfeit medicines account for 15-50% of all available medicines in 
low- and middle-income countries and tend to be more affordable [18]. Counterfeit 
and substandard medicines can have serious health and economic consequences, 
creating a never-ending cycle of poverty in the developing world [19].  
Medicine shortage is another challenging issue that can have serious implications on 
healthcare delivery, economy of the hospital and patient’s health [20]. There are 
many contributing factors that can cause medicines shortages, but the major causes 
that can arise from within healthcare institutions are poor inventory management, 
lack of information flow and communication, changes in clinical practice, increase in 
demands, and natural disasters [20].  Health institutions in Nepal often face 
shortages of essential medicines, especially in remote part of the country [21], and 
during natural disasters like the devastating earthquakes of April and May 2015 [22] 
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and health epidemics such as the repeated emergence of Cholera over several 
years [23]. 
More than half the population of low-income countries in Africa and Asia do not have 
regular access to essential medicines, either due to absence of regulatory authorities 
or limited capacity to regulate medicine distribution [5]. Medicines are the primary 
vehicle for healthcare delivery and have huge impact on the health and well-being of 
people around the globe. Therefore, equitable access to medicines is considered 
one of the fundamental rights of people and vital for achieving several Millennium 
Development Goals such as minimizing child death, improving maternal health and 
fighting against diseases like HIV/AIDS and tuberculosis [5, 24]. With increase in 
adoption of contemporary evidence-based treatment systems, access to medicines 
has become an important topic for research globally [5, 6]. Since medicines cover 
large proportions of total health expenditures, ranging from 40% - 60% in developing 
countries [5, 6], access to health is affected by affordability of medicines [25].  
Therefore, accessibility and affordability of essential medicines has also become a 
growing concern, especially in low and middle-income countries [5, 24, 26] . To 
promote health globally, WHO has attempted to promote access to essential 
medicines, especially to people of developing countries through the Essential 
Medicines List (EML) Programme.  Although this programme has been hugely 
successful in improving accessibility of essential medicines in many low and middle-
income countries, access to medicines is still a huge global problem, especially for 
the underprivileged population [18]. In 2011, a survey conducted on availability of 
essential medicines found that average availability of medicines is less than 60% in 
parts of South-East Asia and Africa. Due to poor availability of medicines in the 
public sector and lack of universal healthcare in many low-income countries, 
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medicines tend to be unaffordable to the majority of population in these countries 
[25]. Although a number of barriers and solutions have been researched for 
promoting access to medicines, ranging from individual to national and international 
level initiatives, a common element among them has been medicine procurement 
[18, 25, 27, 28]. Availability of affordable and evidence-based high quality medicines 
depends on the procurement procedure of medicines and is therefore considered an 
important aspect of healthcare delivery [5].  
Issues of accessibility and affordability of medicines are of paramount importance in 
Nepal [26], in particular, in light of the earthquakes that struck the country in April 
and May 2015, inflicting much damage on its infrastructure, finance and healthcare 
systems. Nepal is a low-income country in South-East Asia and ranks 145th in the 
Human Development Index [29]. The health status of Nepal is poor with mortality 
rate of 190 per 100,000 live births and under-five mortality rate of 42 per 1000 live 
births [30]. Procurement practice in Nepal varies widely depending on whether the 
health institution is governmental, a non-profit organization or a private institution. 
Procurement at public hospitals is conducted in three different ways: central 
push/pull system, district level drug programs, and community drug programs [31]. 
All public procurements are conducted in accordance with the Public Procurement 
Act 2007 and the Public Procurement Guidelines 2009 [32, 33], while private 
hospitals purchase their medicines directly from importers, wholesalers and retailers 
[31]. Although some information regarding procurement and distribution of some 
freely distributed essential medicines procured by the government and donor 
organizations are available [14, 31, 34], procurement practices across all types of 
health institutions of Nepal are still unknown.  Therefore, investigating procurement 
in hospital pharmacies of Nepal based on international guidelines, namely the Basel 
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Statements, is both practical and relevant for effectively improving access to 
affordable high quality medicines.  
This study aimed to investigate medicine procurement practices in hospital 
pharmacies of private and public hospitals of Nepal based on the international 
hospital pharmacy guidelines (FIP Basel Statements 2008) relating to medicine 
procurement. 
3.3. Method 
3.3.1. Ethics 
The study was approved by the ethics committee of authors’ institution [Project No. 
2014/619]. 
3.3.2. Sampling 
Hospital pharmacists or procurement officers at hospital pharmacies in private and 
public hospitals throughout Nepal were included in the study. Samples were 
collected using a passive snowballing technique [35].  
The Hospital Pharmacists’ Association of Nepal, a private company of 
pharmaceutical products, and prominent figures in the profession such as the Vice 
President for the Hospital Pharmacy Section of International Pharmaceutical 
Federation (FIP) in the South East Asian Region were the key contact points for 
searching and reaching out to prospective participants. The only inclusion criterion 
was involvement of the participant in the procurement process. Hospital pharmacies 
that were based inside the premises of a hospital, and were run either by the hospital 
itself or leased by the hospital to a private organization, were included in the study. 
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Hospitals from the five major regions in Nepal as well as those in major cities were 
targeted for inclusion in the study.  
3.3.3. Data Collection and Analysis 
Semi-structured interviews were conducted with key stakeholders using a standard 
interview protocol (Appendix 1; Page 173) based on procurement guidelines of the 
Basel Statements (Table 2) [4] and assessment tools “Measuring Transparency in 
the Public Pharmaceutical Sector” [5] and “Operational Principles for Good 
Pharmaceutical Procurement” [36] published by WHO.  
Interviews were conducted in either Nepali or English based on the participant’s 
preference. The recorded interviews were transcribed and translated to English 
where needed by a bilingual native Nepali speaker. Data collection continued until 
saturation of themes occurred [37]. 
Data were analysed thematically utilising the framework analysis approach [38] 
based on the procurement theme of the Basel Statements [4], with assistance of 
NVivo10 software [39]. Iterative analysis was conducted with continuous consultation 
and discussion amongst the research team until consensus was achieved. 
3.4. Results 
Interviews were conducted with 53 participants; 52 were from hospital pharmacies 
(40 private, 12 public) in four different regions of Nepal. One participant worked at 
the Logistic Management Division under the Department of Health Services of the 
Ministry of Health and Population, and was responsible for procuring free supplies 
for public hospitals and associated health institutions of Nepal (Table 5). 
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Table 5: Sample Characteristics of Nepal 
Sample Sample  Characteristics/Quantity 
Participants  Hospital Pharmacists or Procurement Officers 
Inclusion Criteria for 
Participants 
Involvement in the procurement process 
Sampling Technique Passive Snow Balling 
Key Contact Points 1. The Hospital Pharmacists’ Association of Nepal,  
2. A private company of pharmaceutical products, and  
Prominent figures in the profession such as the Vice 
President of the Hospital Section of International 
Pharmaceutical Federation (FIP) for the South East Asian 
Region 
Area Targeted 5 regions of Nepal 
Area Covered 4 major regions of Nepal 
Public Hospitals 12  
Private Hospitals  37+ 3 (INGO*-funded hospitals) 
Logistic Management 
Division, Department of 
Health Services, Ministry of 
Health and Population, Nepal  
1 
Total Sample 53 
 
Our findings showed the existence of two types of hospital pharmacies, irrespective 
of the type of hospital: 1. those run by the hospital and 2. those run and owned by a 
private organization under a lease agreement. In first type of hospital pharmacies 
those run by the hospital, hospital pharmacies were completely regulated by hospital 
administration/management as a part of hospital’s services. On the contrary, in case 
of privately owned hospital pharmacies, private organization would pay rent for the 
location of the pharmacy and were allowed to run the pharmacy independently for 
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business purpose without any control and governance from the hospital 
administration/governance.  
Statements pertaining to the need for pharmacist-controlled procurement, 
information systems, existence of funding mechanisms, and proper storage 
conditions were all satisfactorily implemented, however, some guidelines were 
implemented only partially. 
Notably, procurement practices were found to be affected by the nature of ownership 
of the hospital pharmacy: hospital-regulated hospital pharmacies tended to be more 
adherent to the Basel guidelines, while privately owned pharmacies deviated.  
Utilising the Basel Statements relating to procurement processes, we organised the 
data under three main themes: Procurement Model, Medicines Selection and 
Contingency Plans. Below are the details of some important findings; all major 
findings are listed in Table 6. 
Table 6: Major findings of Medicine Procurement in hospital pharmacies of Nepal 
 Findings Freque
ncy 
Basel 
Statements
Impleme
ntation 
Status 
Barriers 
A.  Theme 1: Procurement Model   Partial  
1)  Direct Procurement Model Majority Basel 
Statements 
17&20 
  
a)  Purchase of medicines directly 
from wholesalers at a price 
allocated by the manufacturers or 
wholesalers. 
Majority    
b)  Selection of suppliers based on 
past relationships, incentives, 
and/or recommendations of 
pharmaceutical companies. 
Majority    
c)  Absence of suppliers’ evaluation 
system 
Majority    
Chapter 3: Medicine Procurement in hospital pharmacies of Nepal	
 
87 
 
d)  Follows regular procurement 
procedure but lacks well-defined 
written procurement procedure. 
Majority    
      
2)  Competitive Procurement 
Model 
Minority Basel 
Statements 
17&20 
 Prescription-
based selection 
and frequent 
change in 
prescription 
a)  Purchase of medicines through 
either an open bidding process 
with predefined terms and 
conditions or competitive 
negotiations for achieving the best 
price for the medicines required.  
 
Pooled procurement followed by 
the Logistic Management Division 
of the Department of Health 
Services, Ministry of Health and 
Population, Nepal and the 
National Tuberculosis Centre 
(only those supplied by the Global 
Drug Facilities) for purchase of 
limited number of medicines that 
are distributed free-of-cost to 
patients. 
Minority   Requirement of 
the competitive 
process such as 
lengthy and 
complex 
administrative 
process, larger 
order size, time 
and cost 
required for the 
bidding process. 
b)  Selection of suppliers through a 
separate vendor selection 
committee on the basis of 
availability of medicines, 
assessment of services, quality 
and price of medicines, whether 
they were authorised providers, 
their legal record/status, and past 
work experiences. 
Minority    
c)  Existence of suppliers’ evaluation 
system 
Minority    
d)  Existence of well-defined written 
procurement procedure 
Minority    
      
3)  Appeal System  Basel 
Statements 
17&20 
Partial  
a)  Existence of complaints reporting 
system-Verbal 
Majority    
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b)  Existence of complaints reporting 
system-Written 
Minority    
c)  Absence of complaints reporting 
system 
Minority    
      
4)  Expertise Involved  Basel 
Statement 19 
High  
a)  Pharmacists Majority    
b)  Technically competent staffs 
(Trained pharmacy staffs) 
Majority    
c)  Pharmacy Owner (not necessarily 
pharmacists/trained  
Minority    
5)  Information System  Basel 
Statement 23 
High  
a)  Existence of information facilities Majority    
b)  Online sharing of procurement 
related information by Logistics 
Management Division of 
Department of Health Services, 
Nepal 
One    
c)  Absence of any information 
facilities 
Minority    
d)  Telecommunication as a mode of 
interactions with other 
procurement officers 
Several    
e)  Existence of internal networking 
facilities 
Minority    
      
6)  Fund Request Mechanism  Basel 
Statement 24 
Full  
 Existence of fund request 
mechanism 
All    
      
B.  Theme 2: Medicine Selection  Basel 
Statements 
17, 18 & 22 
Partial  
a)  Formulary Selection Minority   Lack of 
formulary 
system and 
Pharmacy & 
Therapeutics 
Committee, 
Authority to 
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doctors for 
medicine 
selection, and 
influence of 
aggressive 
pharmaceutical 
marketing 
b)  Selection based on doctor’s 
prescription 
Majority    
c)  Selection based on national 
Essential Medicine List (EML) 
Majority    
d)  Procurement based on principle 
of procuring for safety 
Minority    
e)  Selection of medicines based on 
quality and/or price of medicines 
Minority    
f)  Influence of Aggressive 
Pharmaceutical Marketing 
Majority    
g)  No influence of pharmaceutical 
marketing 
Minority    
h)  Existence of Pharmacy and 
Therapeutic Committee 
Minority    
i)  Restriction on interactions 
between health professionals and 
marketing representatives of 
pharmaceutical companies 
Minority    
j)  Absence of declaration of conflict 
of interest by health professionals 
Almost all    
      
 Quality Assurance Principle  Basel 
Statement 21 
and 18 
Moderate  
a)  Checking registration status of 
medicine 
Majority    
b)  Trusting doctor’s prescription and 
recommendations, and 
reputations of manufacturers 
Minority    
c)  Quality control system comprising 
of seeking analytical certificates 
and testing samples 
Minority    
d)  Quality assurance based on 
clinical evidences or results  
Minority    
e)  Absence of any quality assurance 
system 
Minority    
f)  Existence of appropriate storage Minority    
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conditions 
g)  Lack of thermostatistically 
controlled temperature 
Almost all    
h)  Availability of unregistered/ 
substandard/counterfeit medicine 
Minority    
      
C.  Theme 3: Contingency Plans  Basel 
Statement 25 
Moderate  
a)  Existence of strategies to manage 
medicine shortages which 
included brand substitution, 
emergency purchasing (from 
outside normal supply system, 
mainly from India), and borrowing 
from other pharmacies, controlling 
inventories and gathering prior 
information from suppliers and 
manufacturers 
Majority    
b)  Existence of funds for emergency 
purchases 
Majority    
c)  Absence of shortage 
management system 
Minority    
 
3.4.1. Theme 1: Procurement Model 
Our study revealed that hospital pharmacies in Nepal tended to use either one or 
both of two types of procurement models: 1.a direct-procurement model or 2.a 
competitive-procurement model. In the direct-procurement model, adopted by the 
majority of hospital pharmacies, medicines were purchased directly from wholesalers 
based on established business relationships, incentives, and/or recommendations of 
pharmaceutical companies, at prices allocated by manufacturers/wholesalers.  
“If we buy from the supplier allocated by medical representatives, they will 
provide us with schemes and facilities. I want to maintain relationships and 
earn profit. Since price is always the same, we negotiate on facilities. When 
we will buy in bulk quantities they may offer us some extra facilities. 
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Therefore, while purchasing medicine, bargaining will be done on such 
things.” [PP40] 
On the other hand, some hospital pharmacies operated under the competitive-
procurement model, following a well-defined written procedure, through either an 
open-bidding process with predefined terms and conditions or competitive 
negotiations for best prices.  
“We call for registration of suppliers with predefined criteria. If the applying 
suppliers meet all those criteria, we will shortlist them through initial 
screening. Then we will ask for quotation from them and will select who offers 
us the best price.” [PP53] 
These differences in procurement models were directly related to pharmacy 
ownership: the competitive-procurement model was typically adopted by hospital 
pharmacies owned by the hospital, while the direct-procurement model was 
implemented by privately-owned hospital pharmacies.  
The study highlighted that pharmacists or trained technical staff were responsible for 
procurement processes in the majority of hospital pharmacies. In a few hospital 
pharmacies, the pharmacy owner, (not necessarily a pharmacist or trained) 
supervised procurement processes.  
The study also revealed that procurement officers in most of hospitals utilized the 
internet, books (e.g. CIMS India; NIDS), company brochures and databases to 
gather information about medicines.  
“We have all sources; primary, secondary and tertiary sources.” [PP18] 
Some hospital pharmacies reported not having access to such resources.  
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Almost all interviewees reported that funds for procurement in their pharmacies were 
generated by sales of medicines. If hospital pharmacies were regulated by hospitals, 
surpluses would be added to finances of the hospital whereas it would be of owner of 
hospital pharmacies in case of privately owned hospital pharmacies. Where 
medicine sales were low, participants reportedly used credit or returned unused 
stock.  
“We can request from the account section which collects bills of purchased 
medicine and money collected from the sales. We can also purchase 
medicine on credit from our regular suppliers.” [PP11] 
3.4.2. Theme 2: Medicines Selection 
Our study confirmed that the majority of hospital pharmacies did not have a 
formulary. Of the few that did adopt a formulary list, it was either devised by a formal 
Pharmacy and Therapeutic (P&T) Committee, or by an informal group of employees. 
Some procurement officers also mentioned considering the national EML while 
purchasing medicines.  
Participants almost unanimously reported that doctors’ prescribing, irrespective of 
the formulary and EML, drove procurement.  
“We have to keep medicines according to doctors’ prescriptions.” [PP30] 
Additionally, almost all of the participating procurement officers reported that 
aggressive marketing strategies of pharmaceutical companies affected medicine 
selection, effectively creating undeclared conflicts of interest.  
"Yes, there are influences. If you look at the whole of Nepal, there are 
influences. Since we don’t have Pharmacy and Therapeutic Committee, 
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medicines are selected based on doctors’ prescriptions. Therefore, 
pharmaceutical companies have become successful in influencing doctors." 
[PP25] 
One participant stated that some pharmaceutical companies donated to the hospital, 
and therefore it was desirable for procurement to be conducted through these 
companies.  
We are practising in this way because we want to provide opportunities to all 
pharmaceutical companies. Sometimes, some companies may have invested 
in the hospital, and then we can discuss with even directors and can use 
medicines of such companies... Everyone’s interest is met. The 
pharmaceutical companies are also here for business... They conduct 
Continuing Medical Education (CME), conferences and other programs. 
Therefore, we will keep medicines from those companies on rotation basis ". 
[PP2] 
Amidst the prescription-driven and commercially-influenced procurement practices, a 
small minority of hospital pharmacies confirmed that procurement was conducted in 
accordance with the Public Procurement Act 2007 without influence of companies. 
"It is very transparent; 100% as per the law. Due to this Commission for the 
Investigation of Abuse of Authority (CIAA), things are very tough now. Public 
Procurement Act is there and we have to follow each and every step as per 
guidelines." [PP8] 
While the majority of hospital pharmacies showed no regulations or policies for 
managing influences of pharmaceutical companies.  
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"This is almost impossible in the context of Nepal because doctors are given 
more priorities and doctors are controlling the hospital rather than being 
controlled by hospital…Therefore, it is impossible to regulate doctors. This is 
more of a national issue rather than a hospital issue. The government has 
published Medicines Promotional Act for managing this and they can 
implement this act; then only will there be some control over this promotional 
strategy…otherwise they are free to continue with their marketing strategy." 
[PP4] 
A few reported to manage influence by restricting pharmaceutical companies’ access 
to decision-makers. 
"Medical representatives are not allowed to visit doctors. We have that rule to 
restrict medical representatives’ visit to our hospital; but meeting outside the 
hospital might happen." [PP50].  
An interesting observation was that such hospital pharmacies tended to be run by 
the hospital and were often owned by the government or International Non-
Governmental Organizations (INGOs). 
On the issue of safety, only a few officers mentioned prioritising safety of medicines. 
Many pharmacists noted that they confirmed the registration status with national 
regulatory authorities before procuring.  
"If medicines are registered in Department of Drug Administration (DDA) then 
we trust that they are of good quality. We only buy registered medicines.” 
[PP2] 
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However, a few hospital pharmacies, especially in cities near the Indian border, 
admitted that they had to procure unregistered medicines from unauthorised sources 
if prescribed by doctors or if medicines required were in shortage. 
"Some medicines are important to patients and are life-saving medicines. 
Doctors have to prescribe such medicines and most of them are not available 
in Nepal. In such conditions when doctors prescribe them, we do purchase 
from India, even from black market. Such medicines are not kept here in the 
pharmacy; we stored them separately and even dispense secretly to patients. 
It is illegal but we are saving patients’ lives." [PP44] 
When asked about adoption of a quality assurance system for controlling entry of 
substandard medicines, some respondents answered that they trusted doctors’ 
prescriptions and recommendations, and/or reputations of the manufacturers for 
ensuring quality of medicines.  
"No, we don’t do that. If doctors prescribe then it must be of good quality. If 
they prescribe then we will sell anything, even stones." [PP20] 
A few participants had a system in place for quality control, including seeking 
certificates of analysis and/or testing of samples.  
"There is a pre-shipment inspection, post-shipment inspection, checking of 
Good Manufacturing Practice and analysis certificates. We appoint a third 
party inspection agency for inspection…It is done for each product and each 
company that won the bid for supply. There is post-shipment inspection at the 
time of delivery. We randomly select medicines and send to national 
medicines laboratories for inspection" [PP15] 
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The study revealed that medicines in most hospital pharmacies were stored in 
appropriate conditions. Many had facilities for maintaining room temperature (20-25 
°C) and other conditions necessary to preserve the quality of medicines during 
storage. 
3.4.3. Theme 3: Contingency Plans 
Our results showed that the majority of pharmacists used brand-substitution, 
emergency-purchasing (from outside the normal supply system, mainly from India), 
and borrowing from other pharmacies, as strategies to manage medicine shortages.  
"We will borrow from other hospital pharmacies or request suppliers to 
manage medicines for us. If it is not possible to manage from these sources 
then we will go for second option. We will discuss with doctors and substitute. 
We also control inventories and try to manage stock.” [PP52] 
Several hospital pharmacists also claimed that they had a separate emergency fund, 
for pricier substitutions needed during emergencies. A few pharmacists stated that 
they did not have a shortage management system in place. 
“If medicines are not available then we have to say no and request patients to 
search in other places.” [PP13] 
Some hospital pharmacies managed inventories by stockpiling up to 3 months’ worth 
of medicines based on past consumption or seasonal changes and epidemics, as 
well as gathering prior information from suppliers/manufacturers to help manage 
medicine shortages.  
“We usually maintain stock for 3 months so shortage does not happen that 
frequently. Sometimes supplier will inform us about upcoming shortages and 
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ask whether we want to order in larger quantities. And in such conditions we 
will order in larger quantity.” [PP14] 
3.5. DISCUSSION 
To our knowledge, this is the first study to explore procurement practices in hospital 
pharmacies in Nepal within the framework of the procurement guidelines of the Basel 
Statements. Our findings revealed mixed results regarding implementation of 
guidelines, which included partial adoption of guidelines in the majority of hospital 
pharmacies. This shows that, by and large, Nepalese hospital pharmacies have 
many good processes in place however there is room for improvement. Accordingly, 
several recommendations are proposed. 
Given the apparent correlation between pharmacy ownership and guidelines 
implementation, enforcement of the Nepalese National Health Policy 2014 [40] and 
Hospital Pharmacy Directives 2013 [41] could be an effective way to improve 
procurement practice and guidelines implementation. These require hospital 
pharmacies to be run or managed by hospital administrations. 
3.5.1. Theme 1: Procurement Model 
The study found that the majority of hospital pharmacies followed the direct-
procurement model, which is considered one of the most expensive models by WHO 
[42], and is thus inconsistent with Basel Statement 20 [4] and the Hospital Pharmacy 
Directives 2013 of Nepal [41]. Moreover, lack of well-defined procurement 
procedures and transparency in supplier selection is also in contrast to Basel 
Statements 17 and 20, which demand transparent, professional and ethical 
procurement practices [4]. According to the WHO, the restricted tender procedure, 
open for only prequalified suppliers, is considered the best procurement model for 
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small countries like Nepal [42]. A small minority of hospital pharmacies adopted a 
competitive-procurement model, similar to other low-and middle- income countries 
like India and those in the Western Pacific region [43]. However the open tender 
system without pre-/post-bidding evaluation of suppliers is not in accordance with 
WHO recommendations [42].  
Furthermore, barriers to utilization of the tendering process were identified, such as 
size of purchase order, stock levels, and administrative workloads, which are similar 
issues reported by WHO [36] and Arney [44]. To overcome these barriers, pooled 
procurement which creates buyers’ cartel for achieving price reductions, improved 
quality assurance and minimization of corruption has been recommended [43]. In 
particular, pooled-procurement with contractual agreements could be adopted [44, 
45]; such models are successfully implemented in countries like, Mexico, Chile and 
within U.S. Department of Veterans Affairs and Department of Defense, and the 
United Nations Organizations [44]. This achieves competitive uniform pricing through 
a centralized tender system, allowing decentralized purchasing of medicine at one 
uniform prices achieved  from central bidding by  all associated healthcare systems 
through smaller repeated orders and delivery [44]. Additionally, several other cost 
containment strategies such as conducting pharmaco-economic evaluation, 
establishing prescribing guidelines and promoting use of generics could be utilized 
by procurement officers while purchasing medicines for hospitals [43, 46].  
Although the  Nepalese National Good Pharmacy Practice Guidelines 2005 [47] 
insists on pharmacist-controlled procurement, in line with Basel Statement 19, this 
was not evident in some hospital pharmacies.  In contrast, the Nepalese Hospital 
Pharmacy Directives 2013 [41]  do not specify this requirement.  Better alignment of 
directives with guidelines should be ensured in the future. This necessitates 
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education on the role of pharmacists in the procurement process and inclusion of 
pharmacist-control in Hospital Pharmacy Directives. Moreover, a multidisciplinary 
approach involving expertise from clinical pharmacology, pharmacoepidomology and 
pharmaco-economics has also been recommended for improving procurement 
practices [13]. 
Reliance on unreliable sources of evidence-based healthcare was also a concern. 
Utilization of readily available online information sources provided by national and 
international organisations providing evidence-based guidelines [e.g. DDA, and 
WHO] should be encouraged. Finally, procurement officers should be educated 
about international guidelines developed by WHO and other international 
pharmaceutical associations [such as FIP] to improve their procurement practices. 
3.5.2. Theme 2: Medicines Selection 
Another challenging issue in pharmaceutical procurement was medicine selection. 
This study found that the majority of hospital pharmacies in Nepal are being 
operated without a hospital formulary to facilitate patient care and medicine 
procurement. This finding suggests that the Basel Statements 18, 21 and 22 [4], the 
WHO [9], American Society of Health System Pharmacists (ASHP) [48] and 
Nepalese Hospital Pharmacy Directives (2013) [41] regarding adoption  of a 
formulary system, were not followed. Hospital pharmacies in Nepal procured 
medicines based on prescription, and the majority of doctors did not utilise a 
formulary system to guide their prescribing behaviour. This is in contrast with 
medicine selection practices in the USA, Europe and Western Pacific countries that 
follow a formulary system [49].  Although a few hospital pharmacies reported the 
existence of a formulary or equivalent list, the selection process was not found to 
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follow guidelines, possibly due to the absence of a formal pharmacy and 
therapeutics selection committee. However, while specific formularies were not 
found to be commonplace in this study, the majority of procurement officers did aim 
to maintain stock of medicines included on the national EML. National List of 
Essential Medicines [50] of Nepal developed by Government of Nepal consists of all 
essential medicines that satisfy health needs and diseases patterns of Nepal and are 
recommended for availability in all health organizations at adequate amount, 
appropriate dosage forms, safety and quality, and affordable price. This adoption of 
national EML indicated some compliance with the procedures recommended by the 
Nepal Pharmacy Council [47] and WHO [42].  
Further, occurrences of undeclared relationships between decision-makers and 
suppliers/manufacturers were also uncovered in this study. The lack of a Pharmacy 
and Therapeutic (P&T) Committee, authority of doctors in medicine selection, and 
influences of aggressive pharmaceutical marketing strategies were reported by 
interviewees as major barriers for formulary-based selection.  
The dominance of doctors driving procurement based on what they prescribe without 
specific prescribing guidelines could be minimized by establishing a P&T Committee 
to develop formularies and add additional players in decision making processes [9] 
with the help of model formularies [national[51] ; international [52]] and guidelines 
published by the WHO [9] and ASHP [48]. Introduction of hospital formularies can 
also be actively taken up by hospital pharmacists of Nepal. 
The influence of pharmaceutical marketing is a heavily scrutinized topic around the 
world because of its impact on patient care. Influence of pharmaceutical companies 
on medicine selection and other procurement-related behaviours evident in Nepal is 
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in contrast with Basel Statement 17 [4], which demands ethical procurement 
practice, and the Basel Statement 18 [4] which emphasizes on the safety of 
medicines. Such influential behaviours to induce prescription and sales of medicines 
have also been reported to pose enormous challenges in India [53], China [54] as 
well as developed countries like the US [11].  To address such issues, medical 
associations in the USA [55] and Australia [56] have attempted to manage 
relationships between medical professionals and pharmaceutical companies by 
implementing strict codes of ethics/conduct. Moreover, the American College of 
Clinical Pharmacy in the USA has developed guidelines for pharmacists to assist in 
managing ethical interactions with pharmaceutical industry [57]. On the contrary, the 
Code of Medical Ethics developed by the Nepal Medical Council [58] is yet to include 
any notes on ethical relationships between healthcare professionals and 
pharmaceutical companies. Although the DDA has developed guidelines on ethical 
promotion of medicines [59], our findings suggest that DDA has not been able to 
effectively enforce them. It is noteworthy that pharmaceutical companies in Australia 
[60] and the USA [61] also have their own codes of conduct that, among other 
guidelines, requires declaration of details of promotional activities to be disclosed. 
Nepalese pharmaceutical companies and regulatory authorities could develop similar 
codes to further promote ethical medicine use.  
Furthermore, undeclared conflicts of interest observed in Nepalese hospital 
pharmacies suggest that there is room to decrease influence and bias. The WHO 
actually suggests establishing guidelines for declaration of conflict of interest by 
people involved in the decision-making processes in order to minimize corruption, 
favoritism or influence, and to increase transparency in procurement processes [5]. 
In line with this, Nepal could make regulatory and practical changes based on the 
Chapter 3: Medicine Procurement in hospital pharmacies of Nepal	
 
102 
 
WHO Good Governance for Medicines Medical Framework [62], which has achieved 
success in countries like Jordan, Thailand and Malaysia [62]. The Nepalese 
government could also introduce a reward-based system like that in the Philippines 
[63] and suggested by Ombaka [6] to encourage organizations to follow regulatory 
guidelines.  
Interestingly, many participants did not seem to consider safety issues whilst 
procuring. Although most procurement officers aimed to procure registered 
medicines to ensure quality,  a few reported procurement of unregistered medicines 
through unauthorised supply chains, especially from India, one of the leading 
countries for counterfeit and substandard medicine production [16]. Procurement of 
medicines from unauthorized sources raises concerns about the safety and efficacy 
of medicines. While it is understood that such procurement practices may only have 
been carried out under exceptionally dire circumstances, regulatory authorities 
should devise a mechanism to tackle this issue. 
 Although a minority took the extra step of checking analysis certificates and 
performing analytical testing, trusting doctors’ prescriptions and the reputation of 
pharmaceutical companies in an environment of incentive-based selection and 
aggressive pharmaceutical marketing may not assure quality of medicine.   
Procurement officers could utilize the model and guide of quality assurance system 
developed by the WHO [64] or the United States Pharmacopeia [65] to develop their 
own internal quality-assurance systems. Inexpensive and easy-to-use analytical test 
kits are also available to facilitate testing to minimize entry of substandard/counterfeit 
medicines [66].  
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In an attempt to combat counterfeiting globally, the WHO has developed a toolkit 
named “BE AWARE” [67] in collaboration with World Health Professionals Alliance. 
The WHO has also established guidelines for the development of measures to 
combat counterfeit drugs [68], which could be a useful resource. Nepal can also 
minimize the risk of purchasing poor quality medicines by utilizing the list generated 
by the WHO prequalification of medicines program [69], especially when purchasing 
from suppliers from countries with high risk of counterfeit medicine production.  
3.5.3. Theme 3: Contingency Plans 
The majority of hospital pharmacies reportedly managed medicine shortages through 
spontaneous workarounds, such as searching for alternatives, emergency 
purchasing, and borrowing from other hospital pharmacies. Some even stockpiled or 
tried to acquire prior knowledge about anticipated shortages, to help overcome 
shortages in epidemics or seasonal demands. These measures were in line with 
some guidelines recommended by ASHP [20], but possibly not sustainable or 
sufficient for managing and achieving preparedness for medicine shortages for the 
long term or times of emergency. The reported lack of shortage management 
systems in few hospital pharmacies indicated that Basel Statements 25 [4] pertaining 
to the existence of contingency plans for medicine shortages was not fully 
addressed. Other countries such as Canada, USA and Europe, have regulatory 
frameworks, preparedness and strategic approaches in place to address medicine 
shortages [70]. Hospital pharmacies in Nepal would benefit from utilizing the three-
phased approach consisting of identification and assessment, preparation, and 
contingency phases, proposed by ASHP for managing shortages of critical or 
essential medicines [20]. This allows for rationing and distributing available 
medicines ethically and purchasing medicines during emergencies with safety, 
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quality and cost of medicine under consideration [20, 71]. Moreover, an information 
system similar to those of developed countries [70] could be utilized, or even made 
compulsory, as in the USA [72], for sharing information on shortages and 
management strategies.  
Nepal recently endured disastrous earthquakes in April and May 2015 causing major 
medicines shortages, which was reported to be a crucial issue of concern in the 
massive aftermath of the tragedy [22]. In such circumstances, adoption of 
preparedness and strategic contingency plans would be of great significance for 
providing timely delivery of health services during emergencies. Hospital 
pharmacies, with active involvement of Ministry of Health and Population, should 
form a plan to address medicine shortages, as well as emergency management of 
medicines.  
3.6. Conclusions 
The findings of this study indicated that procurement guidelines of the Basel 
Statements are currently implemented to a certain extent in hospital pharmacies of 
Nepal. This study also found some significant factors that influenced procurement 
practices in Nepal such as hospital pharmacy ownership, pharmaceutical companies’ 
influences, authority of doctors, and lack of regulatory enforcement. Moreover, 
purchase of unregistered medicines from unauthorised supply chain reported in the 
study showed possibility of health threats by counterfeit and substandard medicines. 
Absence of strategic contingency plans during shortage was also a major concern 
especially as Nepal could be heavily reliant on other countries for essential and 
lifesaving medicines in emergency situations such earthquakes, flooding, other 
natural disasters or health epidemics.  
Chapter 3: Medicine Procurement in hospital pharmacies of Nepal	
 
105 
 
The study reported that existing policies and guidelines comply with the Basel 
Statements and other international guidelines, and national policies of many 
countries to a greater extent. However, implementation of these guidelines were in 
poor practice. Additionally, regulatory constructs were also poor which might provide 
possible reasons for non-compliance to the national regulations. Therefore, it is 
recommended to adopt and regulate existing policies in the beginning and gradually 
amend those policies to meet international standards. Promoting ethical and 
transparent working culture through educational and awareness programs could be 
another important step towards responsible and better procurement practice. These 
recommendations could be helpful in improving accessibility of high-quality, 
evidence-based and affordable medicines as well as preparedness for health 
emergencies during natural disasters and health epidemics, achieving patient care 
goals, and promoting equitable access to health for the general public of Nepal.   
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Chapter 4: How do we procure medicines? A comparative study between 
Australia and Nepal based on the Basel Statements 
This chapter is presented in the form of a manuscript that has been submitted to a 
peer reviewed journal and is currently under review. 
4.1. Abstract 
Accessibility, affordability, safety and quality of medicines are highly influenced by 
medicine procurement. Different countries have different regulatory policies and 
medicine supply management systems resulting in different procurement practices. 
Therefore, we aimed to compare medicine procurement practices of Australia and 
Nepal using framework analysis in the context of international guidelines, namely the 
Basel Statements. Semi-structured interviews were conducted with 22 participants 
from different public hospitals of Nepal and Australia. For the most part, procurement 
practices and their compliance with the Basel Statements in hospital pharmacies at 
public hospitals of Nepal varied from those of Australia in several aspects. 
Nevertheless, a few similarities were also found. Additionally, procurement practices 
that are implemented better in Australia were identified. Adoption and amendment of 
current procurement policies are recommended for improving access to affordable 
and high-quality medicines in Nepal and other developing countries with similar 
medicine access problems and procurement issues.  
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4.2. Introduction 
Hospital pharmacy practice has evolved over the decades from traditional product-
centred practice models to contemporary patient-oriented models of services. Today, 
hospital pharmacists in many countries actively engage in patient care services, 
clinical services, promotion of rational use of medicines, assessment and monitoring 
of therapy, individualized medicine therapy, medicine-use evaluation, and cost-
effective analysis [1, 2].  However, from a global perspective, advancement of 
hospital pharmacy practice still has not been achieved equally in all parts of the 
world. Hospital pharmacy in many countries, especially low and middle-income 
developing countries, has traditional medicine distribution practices and is still 
struggling to establish basic clinical practice [3-5].  For instance, Nepal, a developing 
country [6] has very basic hospital pharmacy practice models focused on drug 
distribution functions [7, 8] whereas Australia, a developed country [9] has advanced 
hospital pharmacy practice models focused on individualized and specialty clinical 
pharmacy services [10].   
The Basel Statements are the international consensus statements developed by the 
Hospital Pharmacy Section of International Pharmaceutical Federation (FIP) in 2008 
for standardizing hospital pharmacy practices around the globe [11-14]. The Basel 
Statements 2008 consisted of 75 statements on six key elements of hospital 
pharmacy practice [12]. Medicine Procurement is one of the six themes included in 
the Basel Statements [12] (Table 2). 
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Table 2: Procurement Guidelines of the Basel Statements 2008 
STATEMENT 
NUMBER 
STATEMENTS 
17 The procurement process must be transparent, professional, and 
ethical to promote equity and access and to ensure accountability 
to relevant governing and legal entities.  
18 Procurement should be guided by the principle of procuring for 
safety. 
19 Procurement of pharmaceuticals is a complex process that requires 
pharmacist control and technically competent staff. 
20 Operational principles for good procurement practice should be 
regularly reviewed and procurement models adapted to fit different 
settings and emerging needs in the most appropriate and cost 
effective way. 
21 Procurement must be supported by strong quality assurance 
principles to ensure that poor quality medicines are not procured or 
allowed into the system. Proper storage to ensure maintenance of 
quality in the whole supply pipeline is mandatory. 
22 Procurement should not occur in isolation, but rather be informed 
by the formulary selection process.  
23 Good procurement must be supported by a reliable information 
system that provides accurate, timely, and accessible information. 
24 A formal mechanism must be in place for pharmacists to request 
designated funds to procure medicines for their patients. 
25 Each pharmacy should have contingency plans for medicines 
shortages and purchases in emergencies. 
 
According to WHO, more than half of the population in low-income countries in Africa 
and Asia were deprived of regular access to essential medicines, due to lack of 
efficient regulatory authority and medicines distribution system [15]. As medicines 
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are the primary vehicle for medical intervention in the modern era, providing access 
to medicines to patients from all backgrounds is an important issue. Medicine 
procurement has huge impact on total health expenditure which ranges from 40% - 
60% in developing countries and has direct influence on availability, affordability, 
safety and quality of medicines [15, 16]. Therefore, exploring the basic yet very 
crucial theme of “Procurement” from the Basel Statements is both practical and 
relevant to developed and developing countries.  
In low-income countries like Nepal, availability of medicines in public hospitals is 
lower than that in private hospitals whereas prices are 66.3% higher in private 
hospitals [17]. Due to poor availability and higher prices of medicines along with lack 
of universal healthcare in many low-income countries, medicines tend to be 
unaffordable for the majority of the population in these countries [18]. The 
government of Nepal has been distributing few selected essential medicines to the 
general public through public health institutions as a part of a free basic health 
program. However, public procurement and the availability of essential medicines in 
public institutions has been reported to be poor [19]. Increasing availability of 
affordable and quality medicines in public health institutions would be beneficial in 
achieving equitable access to medicines to the general public of all background. 
Therefore, this study is focused on exploring medicine procurement in public 
hospitals of Nepal and compare that to public hospitals of Australia. 
Nepal is a low-income developing country in South-Asia [6] ranking 145th position in 
the Human Development Index (HDI) with the HDI value of 0.540 [20, 21]. With 
25.2% of the population living under poverty lines [6], the Gross National Income 
(GNI) per capita (Atlas Method) is US$730 and Gross Domestic Product (GDP) is 
US$19.64 billion [22]. With 5.69% of Nepal’s GDP spent on health, the health status 
Chapter 4: A comparative study between Australia and Nepal 
 
122 
 
of Nepal is poor and has life expectancy at birth of 68 years [22], adult mortality rate 
of 176 per 1000 population [23] and under-five mortality rate of 35.8 per 1000 live 
births [24]. People in Nepal can access health services through three types of 
healthcare facilities: governmental institutions, non-governmental and non-profit 
organizations, and private health institutions [25]. Government institutions provide 
39.04% of total health expenditure and the remaining 60.96% is provided by private 
institutions. External resources from donor organizations accounted for 10.92% of 
total health expenditure of Nepal [26]. The government and donor organizations are 
responsible for funding selected healthcare services and freely distributed 
medicines. People must pay for all other healthcare facilities and medicines [27, 28]; 
which sums up to 48.68% out-of-pocket expenditure of total health expenditure [26]. 
Australia is a high-income developed country in the Western Pacific region [9] with 
the second highest HDI of 0.933 [21], GNI per capita of US$64,620 and GDP of 
US$1.455 trillion [29]. With 9.36% of GDP spent on health, life expectancy at 
birth of Australian people is 82 years [29], adult mortality rate of 61 per 1000 
population [23], neonatal mortality rate of 2.2 per 1000 live births and under-five 
mortality rate of 3.8 per 1000 live births [24]. Health services in Australia are 
provided by public health institutions, which contribute 67.01% of total health 
expenditure and private health institutions which cover the remaining 32.99% of total 
health expenditure. Out-of-pocket expenditure in Australia is only 18.83% of total 
health expenditure with 25.36% of private health expenditure contributed by private 
prepaid plans [26]. 
Public hospitals of Nepal procure medicines in accordance to the Public 
Procurement Guidelines [30] following the Public Procurement Act 2007 [31]. 
Medicine procurement in Nepal is funded completely by sales of medicines. This 
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implies that the costs of medicines are fully paid for by the general public, except for 
a few selected freely distributed essential medicines funded by the government [27]. 
On the other hand, public hospitals in Australia purchase medicines as per supply 
contracts set by their states which are funded by the Australian government [32]. 
And medicines are provided to the general public at affordable government-
subsidized prices [33-35]. 
4.3. Aim  
To compare medicine procurement practices in hospital pharmacies of public 
hospitals of Australia and Nepal.  
4.4. Ethics 
Ethics approval for conducting this study was obtained from the Human Research 
Ethics Committee of author’s institution [Project No. 2014/619]. 
4.5. Method 
4.5.1. Sampling 
Hospital pharmacists or procurement officers at hospital pharmacies of public 
hospitals of Nepal and Australia were contacted using a passive snowballing sample 
collection technique. In snowballing sample collection technique, participants were 
contacted through information provided by other informants or previous participants 
[36]. The only inclusion criterion for participants was involvement in procurement 
procedures. Hospital pharmacists or procurement officers that serviced public 
hospitals in all five regions of Nepal, and the six states and two territories of Australia 
were targeted for inclusion in this study. Hospital pharmacies were selected 
regardless of whether the hospital pharmacy was run by the hospital itself or whether 
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the public hospital leased its pharmacy service from a private organization. In Nepal, 
the Hospital Pharmacists’ Association of Nepal, a private pharmaceutical company, 
and the Vice President for the Hospital Section of International Pharmaceutical 
Federation (FIP) in the South East Asian Region were contacted to assist with 
recruitment of prospective participants. In Australia, the Society of Hospital 
Pharmacists of Australia assisted in the recruitment process. Detailed information 
about sample characteristics is presented in Table 7. 
Table 7: Sample Characteristics of Australia and Nepal 
Sample  Sample  Characteristics/Quantity 
Participants  Hospital Pharmacists or Procurement Officers 
Inclusion Criteria for 
Participants 
Involvement in the procurement process 
Sampling Technique Passive Snow Balling 
Key Contact Points 1. Nepal 
a. The Hospital Pharmacists’ Association of Nepal, 
b. A private company of pharmaceutical products, 
and  
c. Prominent figures in the profession such as the 
Vice President of the Hospital Section of 
International Pharmaceutical Federation (FIP) 
for the South East Asian Region 
2. Australia 
a. The Society of Hospital Pharmacists of Australia 
b. Academics of author’s institution 
Area Covered Nepal: 4 major regions of Nepal 
Australia: 4 states and 2 territories of Australia 
Hospitals Public Hospitals of both countries 
Logistic Management Division, Department of Health 
Services, Ministry of Health and Population, Nepal 
Number of Sample Nepal: 12+1 
Australia: 9 
Total Sample 22 
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4.5.2. Data Collection and Analysis 
For collecting data, a standard semi-structured interview protocol (Appendix 1; Page 
173) was developed based on the procurement guidelines of the Basel Statements 
(Table 2). Additionally, assessment tools “Measuring Transparency in the Public 
Pharmaceutical Sector” [15] and “Operational Principles for Good Pharmaceutical 
Procurement” [37] published by World Health Organization (WHO) were also used to 
assess different aspects of the procurement statements of the Basel Statements 
2008. This interview protocol was utilized for interviewing participants in both 
Australia and Nepal. All interviews in Australia were conducted in English whereas 
participants in Nepal were interviewed either in Nepali or English based on 
interviewees’ choice of language. All interviews were audio-recorded and then 
transcribed verbatim. Transcripts in Nepali language were then translated to English 
by a bilingual native Nepali speaker. Interviews continued until no new concepts 
emerged i.e. saturation of themes [38]. 
The framework analysis approach [39] was used for thematically analysing data, 
based on the procurement theme of the Basel Statements [12]. Framework analysis 
is an analytical approach developed by Ritchie and Spencer which organises data 
based on key themes, concepts and categories, making the process systematic and 
transparent facilitating retrieval and tracking of data [39, 40]. The framework analysis 
approach is used for analysing data with predetermined concepts such as those of 
semi-structured interviews [40]. It is suitable for data covering similar topics or key 
issues that can generate themes capable of providing full description on the 
phenomenon under investigation [40, 41]. The NVivo10 software [42] was used for 
organising data to develop a framework required for analysis. The consensus of the 
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research team was achieved through continuous involvement and discussion in 
iterative analysis. 
4.6. Results 
Interviews conducted with 22 participants from 12 public hospitals and 1 national 
Logistic Management Division of Nepal, and 9 public hospitals of Australia reported 
similarities and differences in procurement practices. Results were thematically 
categorised into four different themes (Table 8) based on nine statements of the 
procurement theme of the Basel Statements 2008. 
Table 8: A comparative study between Australia and Nepal 
 Similarities Frequency Differences Frequency 
1. Operational Principles    
a) Pharmacy Ownership  Pharmacy Ownership-
Hospital 
All 
(Australia); 
Some 
(Nepal) 
   Pharmacy Ownership-
Private 
Some 
(Nepal) 
None 
(Australia) 
b) Procurement Method    
 Mixed type procurement 
method 
All 
(Australia) 
Minority 
(Nepal) 
Direct Procurement 
Method 
Almost All 
(Nepal)  
None 
(Australia) 
 Competitive Procurement 
Method in combination with 
Direct/Negotiation 
Procurement Method 
All 
(Australia) 
Minority 
(Nepal) 
Competitive Procurement 
Procedure  
Australia-State Tender 
Nepal-Hospital Tender; 
Central tender for 
selected free supply 
medicines 
All 
(Australia) 
Minority 
(Nepal) 
 Presence of well-defined 
procurement procedure 
All 
(Australia) 
Outsourcing of Imprest 
Supply System 
One 
(Australia) 
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Minority 
(Nepal) 
None 
(Nepal) 
c) Supplier Selection    
 Supplier Selection by 
hospital/hospital pharmacies 
All (Nepal) 
Minority 
(Australia) 
Supplier Selection by 
state government 
Majority 
(Australia) 
None 
(Nepal) 
 Selection Criteria: 
- Price and Availability of 
Medicines 
- Services provided by 
suppliers 
All 
(Australia 
and Nepal) 
Evaluation of Suppliers-
Documented 
 
All 
(Australia) 
Minority 
(Nepal) 
d) Expertise Involvement    
 Pharmacist and technically 
competent staff involvement 
in procurement process  
All 
(Australia) 
and Majority 
(Nepal) 
Pharmacy owner 
managed procurement 
Minority 
(Nepal) 
e) Funding    
 Funding Source-Government 
and/or International Non-
governmental Organization 
All 
(Australia) 
Minority 
(Nepal) 
Funding Source-Sales of 
Medicines 
Majority 
(Nepal) 
f) Information System    
 Information Resources-
Internet and web-based 
resources 
Majority 
(Australia 
and Nepal) 
Information Resources- 
Research/Survey 
One 
(Australia) 
   Information resources-
Books and Consultation 
with Doctors 
Minority 
(Nepal) 
   Information System-Not 
Available 
One (Nepal) 
2. Evidence-Based Practice    
a) Selection of Medicines  Formulary Selection of 
Medicines;  
Cost-effective, safety and 
clinical evidences based 
Medicines Selection 
All 
(Australia) 
Minority 
(Nepal) 
   Medicines Selection 
based on Prescription 
Majority 
(Nepal) 
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   Medicines Selection 
based on national EML 
Majority 
(Nepal) 
   Medicines Selection 
based on Patient’s Need 
(Non-Formulary\One-Off 
Medicines 
A couple 
(Australia) 
b) Quality Assurance    
 Quality Check Criteria-
Registration Status with 
national regulatory authorities 
Majority 
(Australia 
and Nepal) 
Availability of 
Unregistered Medicines 
Few (Nepal) 
   Checking compliance to 
International Good 
Manufacturing Guidelines 
Majority 
(Nepal) 
   Analytical Quality Testing 
of Medicines 
Some 
(Nepal) 
   Quality Check Criteria-
Risk/Safety Assessment 
Some 
(Australia) 
c) Storage Facilities    
 Appropriate storage 
conditions 
All 
(Australia 
and Nepal) 
Storage Security System 
- Australia-Highly 
controlled manual and 
electronic security 
system 
- Nepal-Manual security 
and scheduled 
monitoring system 
 
3. Professionalism and Ethics    
a) Pharmacy And Therapeutic 
Committee 
 Pharmacy and 
Therapeutic Committee 
Majority 
(Australia) 
Minority 
(Nepal) 
   COI Declaration by PTC 
Members 
Majority 
(Australia) 
One (Nepal) 
b) Influence Of 
Pharmaceutical Companies 
 Influence of 
Pharmaceutical 
Companies 
Majority 
(Nepal) 
None 
(Australia) 
   Approved promotional 
activities of 
Few 
(Australia) 
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pharmaceutical 
companies 
c) Presence of Influence 
Management System 
 
All 
(Australia) 
Some 
(Nepal) 
Absence of Influence 
Management System 
Some 
(Nepal) 
4. Shortage Management    
 Workarounds 
- Substitution  
- Emergency Purchasing 
- Searching and Borrowing  
Stock Management 
Majority 
(Australia 
and Nepal) 
Preparedness and 
Strategic Approach 
- Information Circulation 
- Controlled Usage/ 
Supply  
- Regular Fortnightly 
Meeting for assessing 
availability of 
medicines, probability 
of upcoming 
shortages, stock 
watch and 
preparedness. 
Many 
(Australia) 
   Absence of Shortage 
Management Procedures 
Few (Nepal) 
 
4.6.1. Operational Principles 
The study conducted in hospital pharmacies of public hospitals in Australia and 
Nepal reported a significant difference in the type of hospital pharmacies in these 
two countries. Hospital pharmacies in Australian public hospitals are regulated by 
hospital administration, whereas hospital pharmacies of Nepalese public hospitals 
were found to be regulated either by the hospital or leased by the hospital to private 
organizations. Under lease agreement, the location/s designated for pharmacy are 
rented to private organizations which are then allowed to run their pharmacies on 
their own, independent from the governance/control of hospital 
administration/management. This type of hospital pharmacy is similar to a retail 
pharmacy; the only difference is that it is within the premises of hospitals. 
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In regard to the type of procurement methods used for procuring medicines, 
Nepalese public hospitals reportedly utilized either or both competitive or direct 
procurement methods, with the majority following the direct procurement method. 
With direct procurement methods, medicines were purchased directly from 
wholesalers at prices allocated by manufacturers.   
“We buy directly from wholesalers.” [Nep_PP7] 
Public hospitals of Nepal which followed competitive procurement method reportedly 
conducted their own tendering process at hospital level. 
“We purchase every year through tender process. …We will select suppliers 
that have offered us the lowest price.” [Nep_PP12] 
An exception existed for the purchase of some selected essential medicines that 
were purchased by the central government for free distribution to all public health 
institutions. An interesting finding was that public hospitals of Nepal which regulated 
their own hospital pharmacies reportedly utilized competitive procurement method 
whereas hospital pharmacies that were leased to private organizations were more 
likely to use direct procurement method. 
On the contrary, Australian public hospitals followed competitive procurement 
methods in combination with direct procurement or negotiation methods.  
“That’s mainly done by the state contracts.” [Aus_PP8] 
Public hospitals of Australia either utilized state tenders conducted by state 
government, where all state hospitals were allowed to buy medicines at the price 
negotiated by the state, or called for tender on their own. 
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“In New South Wales, if a drug is listed on the government tender, then we 
are bound to buy that specific brand from the tender… So generally it’s the 
price that’s on tender that will be the cheapest that you can get.” [Aus_PP3]   
Both methods allowed Australian public hospitals to purchase medicines in a cost-
effective manner.  
Hospital pharmacies of both countries had pharmacists and technically competent 
staff involved in the procurement process. However, some of the hospital 
pharmacies in Nepal that were run by a private organization were managed by a 
pharmacy owner who may or may not be a pharmacist/trained person. 
In regard to funding sources for purchasing medicines, all Australian hospitals 
reported being funded entirely by state government; whereas majority of hospital 
pharmacies in Nepal were funded directly by the sale of the medicines. The 
surpluses generated from sales of medicines would then belong to the hospital 
administration if a hospital pharmacy was regulated by the hospital, or belong to the 
owner of the hospital pharmacy if it was privately owned. Procurement of a few 
selected essential medicines, that were included in free distribution list, was however 
funded by the government. Additionally, a couple of hospital pharmacies were 
funded by international non-governmental organizations.  
The main sources of gathering information in hospital pharmacies of Australia were 
the Internet and other Internet-based resources. A few examples included databases 
and direct access to websites of suppliers for obtaining information about product 
prices and availability. Additionally, a few Australian participants reported the use of 
national/state-wide price comparison surveys conducted by an external organization 
for gathering information about price of medicines paid by different hospitals. The 
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majority of hospital pharmacies in Nepal utilized Internet and medicine information 
books like CIMS of India (mainly) and NIDS of Nepal. In addition, a few procurement 
officers of Nepal consulted doctors for any necessary information. One participant 
reported lack of information resources in one of the public hospitals of Nepal.   
4.6.2. Evidence-based Practice 
All public hospitals in Australia followed formulary processes for selecting medicines. 
Participants also reported that public hospitals might use a formulary list formulated 
by the state government, or develop their own formulary for their specific hospitals. 
Regardless of whether they used a state or hospital developed formulary list, patient 
safety, price and quality of medicines, and clinical evidences were major selection 
criteria. 
 “We have the formulary list and we purchase and stock medicines according 
to that list…HPV will meet and look at 1. price, 2. availability, and 3. the 
product itself, that there is no risk. There is big emphasis on medication safety 
to make sure that any products are assessed for risk.” [Aus_PP9]   
In addition to medicines listed in a formulary, some participants stated that 
occasionally they had to procure non-formulary and one-off medicines based on 
clinical needs of patients with approval from Pharmacy and Therapeutics (P&T) 
Committee.  
On the other hand, the majority of procurement officers in hospital pharmacies in 
Nepal selected medicines based on doctors’ prescription. One of the respondents 
added that they had to select medicines based on prescription because they did not 
have P&T Committee and hospital formulary. 
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“We haven’t had a hospital formulary till now. That’s why we keep medicines 
based on doctors’ prescription. We may not be able to keep all prescribed 
brands and so we will keep most commonly prescribed brands.” [Nep_PP9]  
Only a few hospital pharmacies that were managed by hospitals reported to have a 
formulary list of their own. However, the majority of procurement officers in Nepal 
claimed to take into consideration the National Essential Medicines List while 
procuring medicine for their hospital pharmacies. 
“Department of Drug Administration has published narcotic medicines list and 
essential medicines list. We keep all these medicines. We try to keep all 
necessary emergency medicines as well.” [Nep_PP7] 
Sales and price of medicines were other frequently considered selection parameters 
in Nepal.   
In regard to quality of medicines, hospital pharmacies of both countries trusted 
registration of medicines with national regulatory authorities of their respective 
countries. Moreover, the majority of procurement officers in hospital pharmacies of 
Nepal also considered checking whether medicines were manufactured following 
international manufacturing standard. 
 “We usually observe whether they are Good Manufacturing Practice (GMP) 
certified or not; most of the medicines available here are from GMP certified 
company.” [Nep_PP12] 
The study reported that some Australian hospital pharmacies prioritized safety of 
medicines and took extra measures to assess safety, minimizing risk and evaluating 
clinical evidences of medicine. 
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“There is big emphasis on medication safety to make sure that products are 
assessed for risk …Everything that's new is looked and tested by Med-safe 
team.” [Aus_PP9] 
On the contrary, a few hospital pharmacies in Nepal, especially those situated near 
the Indian border, admitted to purchasing of unauthorized medicines when 
prescribed by doctors and when no alternatives were available. 
“Department of Drug Administration should do something on this matter. 
Some medicines are not authorised for entry in Nepal but since doctors have 
prescribed them, such medicines have to be bought illegally.” [Nep_PP10] 
However, some hospital pharmacies in Nepal reported to ensure quality of medicines 
through quality control testing procedure. 
“There is a pre-shipment inspection, post-shipment inspection, documentation 
and GMP certification check. …It is done for each product and each company 
that won the bid for supply.” [Nep_PP6] 
It was found that hospital pharmacies of Nepal that were managed by the hospital 
were more stringent about quality assessment compared to those controlled by 
private organizations. However, a number of procurement officers in Nepal 
reportedly relied completely on doctors’ prescriptions trusting their judgment for 
ensuring quality of medicines. 
All hospital pharmacies in Australia claimed to maintain required storage facilities 
such as appropriate storage conditions, continuous monitoring of storage facilities, 
and highly controlled electronic and manual security systems. Similar facilities were 
reported by the majority of hospital pharmacies in Nepal. However, hospital 
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pharmacies in Nepal did not have provision of continuous monitoring and electronic 
security systems, instead had scheduled manual monitoring and manual security 
systems for controlling unauthorised access. 
4.6.3. Professionalism and Ethics 
All hospital pharmacies in Australia reported to have a Pharmacy and Therapeutic 
Committee (P&T Committee) for selecting medicine and handling medicine-related 
issues in hospital.  In contrast, only a minority of hospital pharmacies in Nepal had 
P&T Committee and the majority did not have any committee as such. The study 
also reported that hospital pharmacies that were managed by hospitals had P&T 
Committees.  
Procurement and medicine selection processes in the majority of hospital 
pharmacies of Nepal were reported to be heavily influenced by marketing strategies 
of pharmaceutical companies.  
“Due to influences of these pharmaceutical companies, medicine selection 
process has been affected by incentives. Since same doctors are working in 
both private and public hospitals, they even tell public hospitals to procure 
medicines of their chosen company.” [Nep_PP7] 
While some participants admitted absence of policies, others claimed existence of 
local and national policies for managing such influences which included restricting 
interactions of doctors and pharmacists with pharmaceutical companies.  
“We don’t have rules.” [Nep_PP10] 
“There is a law by CIAA (Commission for Investigation of Abuse of Authority), 
which says that there should be no influence and corruption; there is no need 
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for any additional rules. If anyone does, then they will be charged by CIAA.” 
[Nep_PP6] 
There was no system for declaring conflicts of interest in the majority of hospital 
pharmacies of Nepal to ensure that the health professionals did not have any 
conflicting relationship with pharmaceutical companies. Furthermore, it was found 
that policies for managing relationships between doctors and pharmaceutical 
companies were likely to exist in hospital pharmacies that were managed by 
hospitals. 
Unlike Nepal, public hospitals of Australia reported that their selection and 
procurement processes were not influenced by pharmaceutical companies; and that 
all decision makers and P&T Committee members have to declare any conflicting 
relationship with pharmaceutical companies.   
“We get some good deals from drug companies, outside the state contract. 
They come in as a deal that if we buy their product, they’ll give us bonus or a 
better price, different things like that will happen……. Sometimes companies 
might give it away for a period of time so that the doctors can get used to 
using it.…. … but then that still has to be approved by the drug committee.” 
[Aus_PP8] 
Moreover, procurement officers in Australia claimed that their hospitals had 
necessary policies., system and working environment for managing relationships 
between pharmaceutical companies and decision makers.  
“We have a code of conduct for medical representatives which are formulated 
by the drug and therapeutic committee and it is based on the fairly clear 
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guidelines of how they should conduct their business when they are in the 
hospital…. based on the code of ethics created by medicines Australia.” 
[Aus_PP6] 
“We cannot control the world but we try to have policies in our hospitals to 
control such issues. We have review processes where we examine these 
issues closely....  We educate staff about faults, give presentation about tricks 
used by pharmaceutical companies, try to raise alerts, create awareness and 
explain about negotiating…all actions are quite transparent.” [Aus_PP2] 
Furthermore, it was found that participants had a great sense of responsibilities and 
accountability of any decisions taken by them as decision makers.  
“You have a lot of power in being able to decide so you really have to be 
careful as a director that you are doing everything ethically and are very 
transparent with the process… you just have to make sure you can justify 
your decision to the board and that there is no perceived conflict of interest.” 
[Aus_PP3] 
4.6.4. Shortage Management 
Substituting unavailable medicines with other available brands or similar type of 
medicines, and supplying medicine through emergency purchasing was a commonly 
used strategy for managing medicine shortages in public hospitals of both countries. 
Other frequently used approaches by procurement officers of both countries were 
workarounds such as borrowing and managing inventories. However, a couple of 
hospital pharmacies in Nepal reported not having any system for managing medicine 
shortages.  
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A significant difference reported between these countries in managing shortages 
was adoption of strategic approaches for handling shortages. Hospital pharmacies in 
Australia had strategic approaches such as gathering prior information, assessing 
and managing availability of medicines, controlling supply and usage, circulating 
information and avoiding stockpiling. 
“One of the meetings we have at our hospital is drug availability meetings 
every two weeks. Basically there is an agenda about stock level, availability 
and usage of medicine. We discuss strategies on what to do…We look at 
many options proactively, try to reduce the risk or manage the product during 
the shortage period by meeting every two weeks, and looking in advance 
what’s happening.” [Aus_PP9] 
Moreover, the majority of participants from Australia reported that they received 
information about medicine shortages through different sources such as the State 
Government, Therapeutic Goods Administration (TGA) (a national regulatory body of 
Australia), and pharmaceutical companies or suppliers. On the contrary, hospital 
pharmacies of Nepal did not always have such strategic plans or resources at hand. 
Information sharing services were also not reported in public hospitals of Nepal. 
4.7. Discussion 
This comparative study is the first study to compare procurement practices in public 
hospitals of Nepal and Australia. This study, conducted in hospital pharmacies of 
public hospitals in Nepal and Australia, showed that there are similarities and 
differences in how medicines are purchased. The study found that public hospitals in 
Australia procure medicines in their hospital pharmacies in accordance with their 
state and national policies, and their procurement procedures comply with those of 
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the Basel Statements. It is a well-known fact that high-income countries like Australia 
have advanced hospital pharmacy practice and well-established professional 
standards [5, 43] and this was also reflected in this study. On the other hand, 
national policies and adoption of the Basel Statements in public hospitals of Nepal 
was found to be enforced only to a certain extent.  
4.7.1. Operational Principles 
Hospital pharmacies of public hospitals in Nepal and Australia both had similarities 
and differences in terms of their operational principles.  An interesting finding of this 
study is the difference in ownership between hospital pharmacies of Nepal and 
Australia. Generally, hospital pharmacies in public hospitals of Australia are 
managed by hospitals. However, in the case of Nepal, some public hospitals 
managed their own hospital pharmacies whereas others provided lease to private 
organizations to run hospital pharmacies in their hospitals. This is in contrast to 
National Hospital Pharmacy Directives of Nepal which demand hospital pharmacies 
be managed by the hospital [27]. Existence of privately controlled hospital 
pharmacies in public hospitals reported in this study suggested that there is lack of 
enforcement and monitoring of national guidelines. An earlier study by Harper et.al. 
in 2007 [44] reported that medicine procurement in Nepal differs according to type of 
health institutions. Our findings indicated that even within the same health institution 
procurement procedures varied depending on types of hospital pharmacies. Hospital 
pharmacies that were controlled by hospitals had one type of procurement procedure 
and those run by private organizations had another type of procurement procedure. 
Moreover, the influences of the ownership of hospital pharmacies on procurement 
procedures observed in this study suggested that compliance to guidelines is more 
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likely to occur if hospital pharmacies are controlled by hospitals rather than if owned 
by private organizations.  
Hospital pharmacies of Australia followed mixed type procurement methods, which 
included a combination of competitive and direct/negotiation procurement 
procedures. Utilization of competitive procurement methods by all public hospitals of 
Australia suggested that all public hospitals of Australia utilized the method that 
complies with the National Medicine Policy [34] and the Commonwealth 
Procurement Rules [45] of Australia which demand utilization of procurement 
methods for achieving value for money, and the Basel Statement 20 which 
advocates for cost-effective procurement model [12]. This was also the same for 
some hospital pharmacies of Nepal, especially those managed by hospital 
administration. But for the majority of hospital pharmacies of Nepal, it was through 
the direct procurement method. This direct procurement method is considered an 
expensive method by WHO [46] and does not comply with the National Drug Policy 
1995 of Nepal [47] and the Procurement Act 2007 [31] recommending competitive 
processes to be in place and the Basel Statement 20 [12] emphasising the notion of 
cost-effectiveness. This choice of procurement method suggested that this could be 
one of many causes of the higher prices of medicines in Nepal compared to 
international reference pricing [17].  
Alternatively, the study found that the government of Nepal had adopted pooled 
procurement for purchasing a few selected essential medicines marked for free 
distribution to all public health institutions. This pooled procurement is considered 
successful in providing competitive prices, by pooling volumes of medicines from 
each institution within the group [48]. This method is similar to that used by India, a 
neighbouring country of Nepal [49], and New Zealand [50].   
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Another significant difference between Australian and Nepalese public 
hospitals was the tendering process.  Reported utilization of state-wide 
contracts by public hospitals of Australia, which allowed all public hospitals to 
purchase medicines at the price negotiated by the state, is considered to be 
effective in achieving best prices as well as reducing time and resources 
required for procurement procedures [51, 52]. This is similar to group 
contracting strategies utilized by the U.S. Department of Veterans Affairs and 
Department of Defense, and international organizations like United Nations 
Children’s’ Fund, United Nations Population Fund and Global Fund. In group 
contracting strategies, a central body within the group will negotiate for price 
through bidding and organizations within the group can purchase individually 
from the selected supplier at that negotiated price [51, 52].  Although similar 
group contracting strategies also have been recommended for low and middle-
income countries like Nepal [53], public hospitals of Nepal still reportedly 
utilized individual tendering processes.  
In addition to pooled procurement and group contracting strategies, other cost-
effective strategies such as use of formularies, rational prescribing guidelines, 
stocking up on less expensive generics, and price regulation [50, 53] have also been 
recommended for low and middle-income countries like Nepal for improving access 
to affordable medicines to the general public.     
Hospital pharmacies of both countries operated in line with the Basel Statement 19 
[12] requiring pharmacists’ control, Statement 23 [12], recommending the existence 
of evidence based information to be at hand, and Statement 24 [12] about funding 
facilities. However, funding sources of these two countries were different. 
Procurement in public hospitals of Australia was funded by the government whereas 
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procurement in public hospitals of Nepal completely relied on sales of medicines 
except for some selected essential medicines that are freely distributed by the 
government.  The reason for this difference is due to variations in healthcare funding 
policies of these countries. Australia provides free/subsidized healthcare facilities, 
including medicines, to its public [32] through Medicare [33] and the PBS system 
[35]. On the contrary, Nepal does not have any public healthcare coverage facilities 
and people have to pay for their medicines [27]. The equity and affordability in 
medicines access could be increased if the government of Nepal might consider 
providing some healthcare subsidization in medicines prices similar to that adopted 
in Australia, especially to poor and needy people who can’t afford medicines and 
may be deprived of basic health needs.  
In regard to information facilities, the use of a national price comparison survey by a 
few public hospitals in Australia is expected to strengthen negotiation power for 
achieving better medicine prices [16]. Governments of both countries should 
consider promoting public accessibility and utilization of such reference prices and 
other medicine-related information in all hospital pharmacies for improving access to 
affordable medicines [54].  
4.7.2. Evidence-based Practice 
The study showed a clear variation in medicine selection process of hospital 
pharmacies of these two countries. Formulary selection processes on the basis of 
patient safety, price and quality of medicines, and the clinical evidence available 
were adopted by public hospitals of Australia. This practice complies with the 
National Medicines Policy [34] and practice standards of Society of Hospital 
Pharmacists of Australia [55], the international WHO guidelines [56],  the ASHP 
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guidelines [57] and the Basel Statements 18, 20, 21, and 22 advocating for formulary 
selection, safety, quality and cost-effectiveness [12].  
Many hospital pharmacies of public hospitals of Nepal on the other hand did not 
have any formularies and selected medicines based on doctor’s prescriptions.  This 
prescription-based medicine selection practice is in contrast with the Basel 
Statement 22 [12] and Hospital Pharmacy Directives 2070 of Nepal [27] which 
recommended formulary selection processes. As formularies have proven to improve 
rational and cost-effective prescribing practices [58], hospitals of Nepal should 
develop their own formularies by utilizing either Nepalese National Formulary [59] 
developed by Department of Drug Administration or model formularies formulated by 
WHO [60]. However, the consideration of a National List of Essential Medicines, by 
some hospital pharmacies for selecting medicines was in line with these guidelines 
to a certain extent. The National List of Essential Medicines [61] is a list of all 
essential medicines required for Nepal and is developed on the basis of diseases 
patterns and health needs of people of Nepal. 
A lack of P&T Committees as a reason for the absence of formularies and use of 
prescription-based medicine selection correspond to one of the three reasons for 
non-utilization of formularies reported by Penm et.al [58]. Additionally, Penm et.al 
[58] did highlight in their study that hospitals’ funding models influenced formulary 
adoption, with public hospitals more likely to have these system in place [58]. 
Interestingly in this study which only focused on public hospitals, we found it was the 
actual funding model of the pharmacy- not that of the hospital that seemed to 
influence formulary use in Nepal.  Hospital pharmacies that were funded and 
managed by hospitals tended to utilise a formulary process for selecting medicines 
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whereas those pharmacies that were contracted by the hospital had limited use of 
formularies.  
We also found that hospital pharmacies of both countries had similar quality 
assurance principles which are on the basis of registration status of medicines. This 
shows that both countries complied with the requirement of the Basel Statement 21 
[12] of having quality assurance principles to ensure purchase of high-quality 
medicines. A comparative multi-country study conducted in 2002 reported that the 
national regulatory authority, Therapeutic Goods Administration (TGA), of Australia 
has well-developed regulatory framework for quality assurance of registered 
medicines [62]. Moreover, special safety and risk minimization strategies adopted by 
public hospitals of Australia for ensuring entry of safe and quality medicines in 
hospital pharmacies reflect strong safety and quality driven working cultures. This is 
in line with the country’s National Medicines Policy 2000 [34] and the Basel 
Statements 18 and 21 [12].   
On the contrary, this study reported incidents of purchase of unauthorised medicines 
in a few hospital pharmacies of Nepal near the Indian border, suggesting lack of 
effective regulatory monitoring of medicine registration. India, a neighbouring country 
to Nepal and the source of many life-saving and essential medicines for Nepal, is 
considered home to counterfeit and substandard medicines [63], and as such can 
increase the possibility of purchasing counterfeit and substandard medicines. 
Although this unauthorised purchase may be the last resort for fulfilling the demand 
for some medicines, this can pose serious health threats - which might add 
economic and health costs burdens to a poor country like Nepal and its poverty 
stricken people. While such malpractice was evident only in a few areas of Nepal 
during certain difficult situations, the study also reported that few hospital 
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pharmacies analytically tested quality of medicines to ensure that all purchased 
medicines were of high quality.  
The Australian regulatory framework and its success in providing high-quality 
medicines to its people could be an example for Nepal to follow for improving its 
current regulatory and monitoring practices. Also, safety and risk minimization 
programs, and systematic working culture that promote safety and quality of 
medicines could be something that can be incorporated in hospitals of Nepal 
gradually in practice. Moreover, Nepal can adapt the WHO recommended model [64] 
and guide [65] for improving its current regulatory policies and work on enforcing its 
current policies and monitoring practices. Hospital pharmacies can also benefit from 
available and affordable analytical test kits that can be used in their own in-house 
laboratories for testing quality of medicines [66]. In addition to this, regulatory 
authorities in Nepal should stringently focus on controlling purchase of  poor quality 
and counterfeit medicines, including in adverse situations of medicines shortages, by 
following WHO guidelines on fighting against counterfeiting [67]. And, with the 
correlation reported between hospital pharmacies’ ownership and quality assurance 
procedures, it appears that controlling privatisation could be a good start towards 
quality purchasing procedure. 
4.7.3. Professionalism and Ethics 
Hospital pharmacies of Australia and Nepal differ in terms of professionalism and 
ethics in practice. The Basel Statement 17 states that procurement should be 
conducted in a professional and ethical manner complying with national policies and 
guidelines [12]. Complying with this statement, all public hospitals of Australia had 
P&T Committee whereas majority of hospital pharmacies of Nepal operated without 
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P&T Committee. The Hospital Pharmacy Directives 2070 [27] of Nepal requires the 
establishment of P&T Committees in all hospital pharmacies of Nepal. However, this 
evidence of lack of P&T Committee in Nepal demonstrates that hospital pharmacies 
of Nepal do not operate in accordance with national practice guidelines. P&T 
Committees are considered responsible for handling all medicine-related matters, 
developing formularies and treatment protocols, and promoting rational and cost-
effective use of medicines [56]. Therefore, in a developing country like Nepal 
establishing P&T Committees could improve access of evidence-based medicine at 
an affordable price to patients of all economic and social background. To assist 
hospitals in establishing P&T Committees, WHO has published a practical guide [56] 
which can be useful for public hospital of Nepal. 
Moreover, this study revealed that, unlike Australian hospital pharmacies, medicine 
selection and procurement processes in the majority of hospital pharmacies of Nepal 
were highly influenced by marketing strategies of pharmaceutical companies. These 
processes, along with undeclared relationships between decision-makers and 
pharmaceutical companies are in contrast to the Basel Statements 17 [12]. While 
such influential practices are common in developing countries such as India [68] and 
China [69], this has also been of concern to developed countries like US [70]. 
Therefore, the United States have developed necessary policies for overseeing 
promotional activities of pharmaceutical companies and relationships between 
pharmaceutical companies and decision makers [71, 72]. Similar policies have been 
developed by Australia [73-75] and well-controlled relationships and promotional 
strategies evident in this study suggested their enforcement. Moreover, perspectives 
of participants on relationship with pharmaceutical companies reflected a deeply 
rooted ethical and responsible working culture and decision making process in 
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Australia. Although, the government of Nepal has also developed guidelines for 
ethical promotion for pharmaceutical companies [76], such influential promotions on 
practice evident from this study suggest that these policies have not been 
implemented in hospital pharmacies of Nepal. Moreover, the code of ethics for 
doctors [77] developed by Nepal Medical Council does not include guidelines on how 
to maintain ethical relationship with pharmaceutical companies. 
4.7.4. Shortage Management 
Hospital pharmacies of both countries have similar strategies for managing medicine 
shortages majorly through substitution, borrowing, emergency purchasing and 
managing inventories. These strategies are closely related with recommendations 
suggested by ASHP guidelines [78]. Existence of shortage management plans 
evident in both countries also indicated that the Basel Statement 25 [12] has been 
adopted. However, unlike hospital pharmacies of Australia, Nepalese hospitals did 
not have any strategic plans for preparedness and shortage minimization; instead 
overstocked medicines - which further created medicine shortages. Moreover, this 
study reported information sharing initiatives taken by hospitals, state government, 
TGA, and suppliers of Australia which was similar to those of other developed 
countries [79]. Nepal did not have any type of information sharing strategies at either 
local or national levels. Another concerning issue was lack of contingency plans in 
few hospital pharmacies. This can be crucial for countries like Nepal where 
medicines shortages are common due to various reasons like difficult geographical 
areas [80], earthquakes [81], health epidemics [82] and political instability [83] 
making existence of strategic plans even more important.  
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The success stories of Australian hospital pharmacies revealed in this study might 
be useful for Nepal. Alternatively, hospital pharmacies can utilize ASHP guidelines 
[78] for managing shortages strategically. Additionally, the government of Nepal 
could take national initiatives similar to those of Australia and the United States [84] 
for improving availability of medicines especially.    
4.8. Conclusions 
Procurement practices of majority of public hospitals of Nepal varied from those of 
public hospitals of Australia in several aspects however there were a few similarities. 
Wide adoption of national policies and the Basel Statements was reported in hospital 
pharmacies of Australia, whereas it was reported only to some extent in hospital 
pharmacies of Nepal. However, it is to be noted that this study was conducted with 
the assumption and findings that high-income countries like Australia have better 
procurement practices; and its procurement procedures could be utilized to propose 
first-hand practical recommendations to improve current procurement practices of 
Nepal.  
Privatization of hospital pharmacies, lack of cost-effective procurement method, 
prescription-driven medicine selection processes, the influence of pharmaceutical 
companies in undeclared relationships between decision-makers and 
pharmaceutical companies, the availability of unregistered medicines, and lack of 
preparedness and strategic plans for handling medicine shortages were all major 
concerns reported in this study. These issues suggest that current procurement 
practices of hospital pharmacies of Nepal still need to implement its own national 
policies and guidelines in practice. However, this partial compliance reported in 
Nepal suggested that Nepal is heading in right direction and its current procurement 
practice could be improved to meet international standards.  
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Adoption and regulation of national policies and guidelines are therefore 
recommended for improving procurement practices of public hospitals of Nepal. 
International policies and guidelines, and successful strategies from other countries 
could be utilized to amend and update existing national policies and guidelines in a 
way to suit health needs and priorities, regulatory and administrative framework, and 
financial capabilities of Nepal. In particular, competitive procurement methods like 
pooled procurement with group contracting strategies, price-subsidization, ethical 
work culture, and formulary selection process based on safety, quality and cost-
effective principles, which are successfully implemented in Australia, are 
recommendations for improving access to affordable and high-quality medicines in 
Nepal. While adopting international guidelines and strategies, further studies are 
recommended to research the suitability and feasibility of those guidelines in the 
context of Nepal and also identify necessary adaption steps required. Moreover, 
working on promoting ethical, transparent and professional work culture and 
developing systematic operational principles in Nepal could be helpful in achieving 
procurement goals. 
Efforts are ongoing at both national and international levels to improve equity in 
medicine access in Nepal and other developing countries. To that end, these 
recommendations based on evidence from Australian procurement systems and 
national and international guidelines should be highly useful for improving access to 
affordable and quality medicines in Nepal and other developing countries.   
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Chapter 5: Conclusions and Recommendations 
5.1. Conclusions 
The aim of this study was to explore how medicines are purchased in hospital 
pharmacies of Nepal and Australia, and study whether these practices comply with 
international guidelines, namely the Basel Statements. Additionally, this study also 
aimed to identify barriers and facilitators regarding implementation of guidelines and 
to provide evidence-based recommendations to improve the current medicine 
procurement practice in Nepal. This was the first study to explore medicine 
procurement practices of Australia and Nepal based on the Basel Statements. 
A literature review on the procurement theme of the Basel Statements revealed that 
many aspects of medicine procurement were unexplored and a thorough study to 
include all aspects of procurement practice was needed. This review revealed that 
studies were focused mainly on corruption, transparency, counterfeiting, price 
control, quality of medicines, and medicine selection process. Quality assurance 
principles, information facilities, financing/funding systems and storage facilities were 
factors that had not received adequate coverage. The review identified some other 
factors such as marketing strategies of pharmaceutical companies, undeclared 
conflict of interests, unethical practices, and contingency plans that could influence 
procurement practices, especially in developing countries like Nepal. This study also 
revealed that selection of medicines and procurement methods was crucial for 
improving access to affordable and quality medicines. The observed lack of 
information about medicine procurement practices in Nepal suggested that there was 
a need to conduct comprehensive studies and publish information about medicine 
procurement in Nepal from individual, organizational and national perspectives. 
Chapter 5: Conclusions and Recommendations	
 
164 
 
A qualitative study on medicine procurement practice in hospital pharmacies of 
Nepal was conducted to study current procurement practices, explore 
implementation of the Basel Statements, identify facilitators and barriers, and 
propose recommendations to improve current procurement practices. Semi-
structured interviews were conducted and data were analysed thematically using the 
framework analysis method. The results of this study showed that procurement 
guidelines of the Basel Statements were adopted to a certain extent by a majority of 
hospital pharmacies and to a greater extent by select hospital pharmacies of Nepal. 
However, some aspects of medicine procurement such as expertise, information 
resources, storage facilities and availability of funds, complied with the Basel 
Statement to a greater extent. Some barriers that affected implementation of national 
guidelines and the Basel Statements, as reported by study participants, were: 
leasing provision of hospital pharmacies to private organizations, influences of 
pharmaceutical companies, full authority of doctors on medicine selection, lack of 
formulary systems, and lack of regulatory enforcement. The procurement method 
utilized by the majority of hospital pharmacies was found to be the “direct” 
procurement method, which is comparatively more expensive than other competitive 
methods. However, there were a few exceptions, in which pharmacies utilized a 
competitive tendering process to achieve the lowest possible price. While medicine 
selection should follow a formulary process, only a small number of hospital 
pharmacies had a formulary system in place and the majority of hospital pharmacies 
selected medicines completely based on doctors’ prescriptions. Nonetheless, the 
National List of Essential Medicines was found to be taken into consideration by 
most pharmacies. In addition to this, prescription-driven selection processes, 
undeclared conflicts of interests and influential medicine selection process was one 
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of the concerning issues about ethical and transparent procurement procedure in the 
majority of hospitals of Nepal. However, procurement procedures of a few hospitals 
were under national scrutiny by CIAA and other regulatory departments.   
Although few hospitals in Nepal undertook quality-testing procedures for ensuring 
quality of medicines purchased, the majority relied on testing undertaken by national 
regulatory authorities. It has been debated whether reliance on national regulatory 
authorities is an effective and strong quality assurance principle for developing 
countries like Nepal that are susceptible to the entry of counterfeit and substandard 
medicines across their borders. The findings of this study suggested that such 
reliance on national authorities is not effective, as unregistered medicines were 
evident in a few hospitals of Nepal near the Indian border.  
And while shortage management plans were prevalent, lack of strategic contingency 
plans was identified as a point of concern for Nepal, given that Nepal has to import 
most life-saving medicines and is prone to natural disasters, health epidemics, 
political instabilities, and geographical difficulties that make medicine shortages 
almost unavoidable. Collectively, these findings indicate that hospital pharmacies in 
Nepal are taking steps along the right path, but the country needs changes in order 
to achieve greater compliance with its own national standards and be on a par with 
international standards.  
Furthermore, our comparative study between medicine procurement practices of 
Nepal and Australia based on the Basel Statements, revealed variations in the extent 
to which procurement guidelines of the Basel Statements were implemented in these 
two countries. As expected, Australian practice was found to comply with the Basel 
Statements to a greater extent compared to Nepalese practice. However, quality 
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assurance principles, information sources, shortage management plans, and 
expertise involvement were some aspects of Nepalese procurement practices that 
were comparable to those of Australian practice and consistent with the Basel 
Statements. However, factors such as ownership/management of hospital pharmacy, 
procurement methods, medicine selection processes, regulatory frameworks, and 
financing systems were areas in which Nepal differed from Australian practices and 
failed to comply with the Basel Statements.  
A significant difference between the two countries was how relationships between 
key stakeholders and pharmaceutical companies were perceived and managed. 
Strong policy-based enforcement of ethical relationships and pharmaceutical 
marketing were evident in Australia, whereas heavy industry influences on 
procurement practices, due to a lack of policies to manage conflicts of interest, were 
found in Nepal. Although Nepal did not have specific policies for managing ethical 
relationships between health professionals and pharmaceutical industries), public 
procurement procedures were subject to scrutiny by CIAA and governmental 
regulatory bodies for assessing corruption and abuse of authority. Moreover, drug 
regulatory authorities were found to make efforts to ensure ethical promotion of 
medicines by pharmaceutical companies, which could be considered a good start. In 
addition to ethical policies, this study also found self-awareness and perceptions of 
accountable and justifiable decision-making ingrained in Australian practice, which 
may serve as a good lesson for policy and decision makers of Nepal. Moreover, 
safety and quality principles were found to be incorporated in routine practice in 
public hospitals of Australia, which were lacking in the majority of hospital 
pharmacies of Nepal. Such principles are urgently needed in Nepal, especially given 
the evidence of purchasing of unregistered medicines of dubious quality from 
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unauthorized suppliers. Furthermore, despite Nepal being susceptible to medicine 
shortages due to the country’s vulnerability to natural disasters, as well as health 
epidemics, and political instabilities, there was a clear lack of preparedness to deal 
with medicine shortages. Strategies for minimizing shortages should be considered 
an urgent issue requiring immediate action.  
Although the above-mentioned description of hospital pharmacies in Nepal were 
applicable to the majority of hospital pharmacies, it is noteworthy that a few were 
found operating in accordance to national policies and guidelines to procure cost-
effective, high-quality and safe medicines by following a competitive procurement 
method and formulary selection process, and making a clear effort to ensure that the 
purchased medicines were of good quality.  
In conclusion, our findings indicated that medicine procurement practices in Nepal 
differed from that of Australia in many aspects and exhibited poor compliance to the 
Basel Statements. Nevertheless, some aspects of Nepalese medicine procurement 
procedures were on par with those of Australia and complied with the Basel 
Statements in a few key areas. Although compliance to national and international 
guidelines were relatively poor and their procurement practices appeared to be in 
need of major improvements, hospital pharmacies of Nepal were found to be 
generally progressive and on the right path towards meeting international standards. 
5.2. Recommendations 
This study successfully examined the medicine procurement practices of Australia 
and Nepal, compared them, and proposed evidence-based recommendations to 
improve current medicine procurement practices in Nepal. Although this qualitative 
study did not cover all hospitals of Nepal and Australia and may not be completely 
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generalizable, major hospitals from most regions of Nepal and several states of 
Australia were included and therefore provide meaningful insights into medicine 
procurement practices in Nepal and Australia. The study was restricted to public 
hospitals of Australia and Nepal, so inclusion of private hospitals from the two 
countries in future studies is recommended. This study involved interviews with 
hospital pharmacists and procurement officers however, perspective of policy 
makers, national regulatory authorities and hospital administrators could have 
provided in-depth and first-hand idea on practical challenges on guidelines adoption, 
regulation and implementation, and providing recommendations that were feasible 
and applicable to Nepal. Further studies are recommended to conduct research with 
the explore these key stakeholders and explore these above mentioned issues. 
Owing to the influence of ownership of hospital pharmacies on different aspects of 
procurement, strict monitoring and enforcement of national policy against 
privatisation of hospital pharmacies is the simplest starting step for Nepal. Although, 
the government of Nepal has already started legal actions and monitoring initiatives 
against leasing agreements of hospital pharmacies, enforcement is still poor.  
Hospital pharmacies of Nepal should utilize appropriate procurement methods that 
are transparent and free of any influences and corruption, allowing purchase of cost-
effective and evidence-based high quality medicines to maximize utilization of the 
limited resources available. Group-contracting strategies utilized by Australian public 
hospitals and many other countries and international organizations could offer one 
solution for Nepal.  
Strong regulatory framework, efficient operational principles, well-managed 
procurement processes, ethical and professional organisational culture, and safety 
and quality principles ingrained deeply in policies and practice are some 
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recommendations that have been drawn from Australian practice for improving both 
national and international guidelines implementation in Nepal.  Also, this study highly 
recommends changing perceptions of key stakeholders in Nepal through education 
and creating suitable working environments that foster ethical and safe practices. 
Being a relatively poor country, Nepal is in dire need of ethical and safe practices to 
maximize utilization of limited resources, particularly in cases of medicine shortages. 
Assessing availability, managing inventories, circulating information to alert 
upcoming or existing medicine shortages, and rationing usage/ distribution of 
available medicines, in conjunction with existing shortage management plans, could 
be the suitable strategy for tackling repeated occurrences of medicine shortages in 
Nepal, especially in light of recent earthquakes and blockades of the India-Nepal 
border. 
It is a well-known fact that it is impossible to simply transplant the practices of 
developed countries to developing countries. Nepal needs to carefully scrutinize its 
own situation and with awareness and a will for change, should implement 
incremental changes towards improving affordability and availability of high-quality 
medicines, patient safety, ethical working habits, and preparedness for health 
emergencies. Therefore, strengthening its own national policies and guidelines to 
meet international standards and working efficiently on their enforcement would be 
an effective approach for overcoming existing barriers and improving accessibility 
and affordability of high-quality medicines in Nepal. Moreover, developing efficient 
work cultures, changing perceptions of key stakeholders through educational and 
awareness programs, and strengthening policy enforcements are all important for 
achieving these goals.  
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Table 10 below summarizes procurement issues reported in Nepal and 
recommendations to improve the current procurement practice of Nepal based on 
evidence-based procedures of Australia and other international guidelines: 
Table 9: Summary of Procurement Issues and Recommendations 
 Procurement Issues Recommendations 
1 Hospital pharmacies operated by 
private organizations on lease 
agreements 
- Strengthening national regulatory enforcement 
against leasing provision of hospital pharmacies 
2 Utilization of the expensive direct 
procurement method 
- Use of group contracting strategies such as pooled 
procurement to facilitate individual purchase while 
still receiving group-negotiated prices. 
3 Prescription-driven selection of 
medicines 
- Implementation of a formulary system and P&T 
Committee system and breaking the monopoly of 
an individual or biased group over decision-making. 
4 Lack of transparency in practice; 
undeclared conflict of interest and 
influential decision making and 
procurement practice 
- Strengthening regulatory policies and their 
enforcement 
- Policy amendment to include policies for ethical 
relationship between decision makers and 
pharmaceutical companies 
- Creating ethical working habits; promoting ethical 
work environment; and educating and creating 
awareness for making the decision-making process 
accountable. 
5 Weak quality assurance principles - Strengthening national regulatory authorities for 
making the quality testing procedure more effective. 
- Adoption of pre- and post-qualification process by 
hospital pharmacies or a group before purchasing 
medicines, especially from a new or suspicious 
supply chain. 
6 Purchase of unregistered 
medicines in few hospital 
- Strong regulatory monitoring of distribution and 
marketing of medicines to avoid entry of 
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pharmacies near Indian border, 
especially during medicine 
shortages 
unregistered medicines. 
- Checking quality of medicines before purchasing to 
avoid counterfeit and substandard medicines, 
especially during emergency purchase.  
7 Lack of strategic contingency plans - Adoption of preparedness strategies such as 
assessment of medicine availability, managing 
inventories, information circulation about upcoming 
shortages and managing strategies at national and 
local levels.  
- Rational use and distribution of the available stock 
of medicines. 
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Appendix 1: Interview Protocol 
Step 1 
Introduction and greeting 
Step 2 
Reiteration of participation options (withdrawal etc), organise consent form signing 
and ask for permission to start audio-taping 
Step 3 
Start interview- allow participant to speak without prompts. Use prompts only if the 
flow lulls somewhat. 
Interview Questions 
1. How do you procure medicines in your hospital? 
Prompts: 
a. Does your hospital have Standard Operating Procedure for the 
procurement? 
b. Are the decisions made by selection committee publicly disseminated? 
If yes, where? 
c. Is the procurement of medicines based on evidence of safety? National 
essential medicines list or hospital formularies? 
d. Are pharmacists involved in the procurement procedure? If not, who is 
the responsible person for handling the procurement process?  
 
2. Are there competitive procedures for the procurement of medicines? 
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If yes, prompts: 
a. Are the contract specifications publicly available and distributed with 
tender documents? 
b. Are tenders and tender results publicized?  
c. Are there specific criteria for tender committee membership? Is the 
membership permanent? 
 
3. Does your hospital have Pharmacy &Therapeutics Committee [PTC], 
formulary list, standard treatment guidelines and formulary manual?  
If yes, prompt: 
a. If a PTC is present, who are the members of the committee?  
b. Are there clear criteria for selection committee membership? If yes, 
what are they? 
c. Do terms of reference exist which describe the purpose of the selection 
committee, its composition, processes and duration?  
d. Are there clear rules for decision-making for the committee decisions? 
Is the decision made in a democratic manner? 
e. Is there a conflict of interest form that members of the selection 
committee and tender committee are obliged to complete? Are there 
clear sanctions for breach of these regulations? 
f. Is there a law or regulation prohibiting members of the drug selection 
committee from accepting support in kind or in cash from 
pharmaceutical companies? 
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4. Are there clear written criteria for adding and removing medicines for 
formulary list? If yes, what are they? 
a. Is the inclusion of medicines in the formulary list based on evidence of 
cost-effectiveness and health needs? 
b. Is there a clear algorithm, based on utilization of services and health 
needs to determine quantity and type of medicines purchased? 
 
5. Is quality of medicines tested as a part of procurement procedure? If yes, 
which method do you follow? Prequalification or Post-qualification or both? 
Does your have own in-house quality control laboratories? Where are they 
tested? 
 
6. Is supplier performance monitored annually? 
 
7. Do your hospital storage facilities satisfy the desired storage conditions of all 
medicines? Are storage facilities accessible to all? If no, who is/are the 
authorized person/s for access? 
 
8. What type of security system is present in your storage facilities? Manual or 
Electronic? 
 
9. Does your hospital have information system for tracking the procurement 
procedure, communication exchange, international reference pricing and 
other useful resources? 
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10.  Is there a management information system used to report product problems 
in procurement? 
a. Is the information obtained from monitoring used to influence future 
procurement decisions? 
b. How are medicines shortages managed in the hospital and how are 
they purchased during emergencies? 
 
11. How is procurement of medicines funded in the hospital? Is there existence of 
any funding mechanism for requesting funds? 
 
Thank the participant and ask if they wish for feedback in the form of a summary of 
findings. 
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Exploring procurement through the lens of the Basel 
Statements: a comparative study between Australia and Nepal 
 
PARTICIPANT INFORMATION STATEMENT 
 
(1) What is this study about? 
 
You  are  invited  to  take  part  in  a  research  study  comparing  procedures  of 
procurement of medicines  in hospitals  in Australia and Nepal. Hospital pharmacies 
are generally  responsible  for medicines procurement, and practices differ around 
the world. We would like to ask you about procedures of medicine procurement in 
your practice. 
 
You have been  invited to participate  in this study because we have found, or have 
been told by the relevant Hospital Pharmacy Association in Australia or Nepal, that 
you are the Pharmacist in charge of procurement in your department or hospital.   
 
This Participant Information Statement tells you about the research study. Knowing 
what  is  involved will help you decide  if you want to take part  in the study. Please 
read  this  sheet  carefully  and  ask  questions  about  anything  that  you  don’t 
understand or want to know more about.  
 
Participation in this research study is voluntary. So it’s up to you whether you wish 
to take part or not.  
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By giving consent to take part in this study you are telling us that you: 
 Understand what you have read 
 Agree to take part in the research study as outlined below 
 Agree to the use of your personal information as described. 
 
You will be given a copy of this Participant Information Statement to keep. 
 
(2) Who is running the study? 
 
The  study  is  being  carried  out  by  the  following  researchers  from  the  Faculty  of 
Pharmacy, University of Sydney: 
 Dr Betty Chaar  
 Dr Rebekah Moles 
 Ms Mina Shrestha 
 
Ms Mina Shrestha is conducting this study as the basis for the degree of Master of 
Philosophy at The University of Sydney. This will take place under the supervision of 
Dr Betty Chaar and Dr Rebekah Moles 
 
(3) What will the study involve for me? 
 
You will be asked to participate in an interview at a location of convenience for you.  
We are seeking your perspective on procurement of medicines procedures  in your 
institution. We are interested in whether procurement processes follow any specific 
guidelines  or  carried  out  in  a  different manner,  and what  that manner may  be. 
These interviews will be conducted in English in both Australia and Nepal.  
 
The interview will be tape recorded with your permission, to enable us to transcribe 
later.  We  will  send  you  the  transcript  for  confirming  its  accuracy  and  any 
emendations you wish to make, if you agree. 
 
(4) How much of my time will the study take? 
 
We anticipate the interview to take no longer than half an hour. 
 
(5) Do I have to be in the study? Can I withdraw from the study once I've started? 
 
Being  in this study  is completely voluntary and you do not have to take part. Your 
decision whether  to participate will not affect your  current or  future  relationship 
with the researchers or anyone else at the University of Sydney. 
 
If you decide to take part in the study and then change your mind later, you are free 
to  withdraw  at  any  time.  You  can  do  this  by  notifying  us  at  any  time,  with  no 
consequence whatsoever. 
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You are free to stop the  interview at any time. Unless you say that you want us to 
keep  them, any  recordings will be erased and  the  information you have provided 
will  not  be  included  in  the  study  results.  You  may  also  refuse  to  answer  any 
questions that you do not wish to answer during the interview. 
  
(6) Are there any risks or costs associated with being in the study? 
 
Aside  from giving up  your  time, we do not expect  that  there will be any  risks or 
costs associated with taking part in this study. 
 
(7) Are there any benefits associated with being in the study? 
 
We  cannot  guarantee  or  promise  that  you  will  receive  any  direct  benefits  from 
being in the study. 
 
(8) What will happen to information about me that is collected during the study? 
 
By providing your consent, you are agreeing to us collecting only a minimal amount 
of  personal  information  about  you  for  the  purposes  of  this  research  study.  Your 
information  will  only  be  used  for  the  purposes  outlined  in  this  Participant 
Information Statement. 
 
All data collected from the recordings of interviews will be de‐identified – allocating 
only a number to the interview to allow us to analyse the data. No one other than 
the researchers will have access to the data.  
 
Your  information will be stored securely  in  the supervising researcher’s office and 
your  identity/information  will  only  be  disclosed  with  your  permission,  except  as 
required  by  law.  Transcripts  and  recordings will  be  destroyed  completely  after  7 
years.  Study  findings  may  be  published,  but  you  will  not  be  identified  in  these 
publications. 
 
(9) Can I tell other people about the study? 
 
Yes, you are welcome to tell other people about the study. 
 
(10) What if I would like further information about the study? 
 
When  you  have  read  this  information  Ms  Mina  Shrestha  [mobile  number: 
0450229179]  will  be  available  to  discuss  it  with  you  further  and  answer  any 
questions you may have.  If you would  like  to know more at any  stage during  the 
study,  please  feel  free  to  contact  Dr  Betty  Chaar  [Work  Phone  Number: 
+61290367101, Mobile:+61 425210547; Email: betty.chaar@sydney.edu.au] 
 
(11) Will I be told the results of the study? 
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You have a right to receive feedback about the overall results of this study. You can 
tell us that you wish to receive feedback by ticking the relevant box on the consent 
form. This feedback will be in the form of a one page lay summary]. You will receive 
this feedback after the study is finished.  
 
(12) What if I have a complaint or any concerns about the study? 
 
Research  involving  humans  in  Australia  is  reviewed  by  an  independent  group  of 
people called a Human Research Ethics Committee  (HREC). The ethical aspects of 
this study have been approved by the HREC of the University of Sydney [Project No. 
2014/619]. As part of this process, we have agreed to carry out the study according 
to  the  National  Statement  on  Ethical  Conduct  in  Human  Research  (2007).  This 
statement has been developed to protect people who agree to take part in research 
studies. 
 
If you are concerned about  the way  this  study  is being conducted or you wish  to 
make  a  complaint  to  someone  independent  from  the  study,  please  contact  the 
university using the details outlined below. Please quote the study title and protocol 
number.  
 
The Manager, Ethics Administration, University of Sydney: 
 Telephone: +61 2 8627 8176 
 Email: ro.humanethics@sydney.edu.au 
 Fax: +61 2 8627 8177 (Facsimile) 
   
 
For the Nepalese arm of the study, if you have any concerns or wish to make a complaint, 
please contact: 
 Nepal Health Research Council 
  Ramshah Path; P.O.Box 7626 
  Telephone No.: 977‐1‐4254220/4227460 
Fax: 977‐1‐4262469/4268284 
Email: nhrc@nhrc.org.np 
 
 
 
 
 
This information sheet is for you to keep 
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Exploring procurement through the lens of the Basel 
Statements: a comparative study between Australia and Nepal 
 
PARTICIPANT CONSENT FORM 
 
I, ................................................................................... [PRINT NAME], agree to take part in this research 
study. 
 
In giving my consent I state that: 
 
 I  understand  the  purpose  of  the  study,  what  I  will  be  asked  to  do,  and  any  risks/benefits 
involved.  
 
 I  have  read  the  Participant  Information  Statement  and  have  been  able  to  discuss  my 
involvement in the study with the researchers if I wished to do so.  
 
 The researchers have answered any questions that  I had about the study and  I am happy with 
the answers. 
 
 I understand that being in this study is completely voluntary and I do not have to take part. My 
decision whether  to  be  in  the  study  will  not  affect my  relationship with  the  researchers  or 
anyone else at the University of Sydney now or in the future. 
 
 I understand that I can withdraw from the study at any time. 
 
 I understand  that  I may  stop  the  interview at any  time  if  I do not wish  to continue, and  that 
unless I indicate otherwise any recordings will then be erased and the information provided will 
not be included in the study. I also understand that I may refuse to answer any questions I don’t 
wish to answer. 
 
 
 
 
 
Faculty of Pharmacy
   ABN 15 211 513 464   
  CHIEF INVESTIGATOR 
Dr Betty Chaar 
Senior Lecturer in Pharmacy Practice 
Room S242
Pharmacy and Bank Building A15
The University of Sydney 
NSW 2006 AUSTRALIA
Telephone:   +61 2 9036 7101
Facsimile:    +61 2 9036 7097
 Email: betty.chaar@sydney.edu.au
Web: http://www.sydney.edu.au/
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 I understand that personal information about me that is collected over the course of this project 
will be stored securely and will only be used for purposes that I have agreed to. I understand 
that information about me will only be told to others with my permission, except as required by 
law. 
 
I understand  that  the  results of  this  study may be published, but  these publications will not 
contain my name or any identifiable information about me unless I consent to being identified 
using the “Yes” checkbox below. 
 
 Yes, I am happy to be identified. 
 
 No, I don’t want to be identified. Please keep my identity anonymous. 
 
 
I consent to:  
 
 Audio‐recording      YES    NO   
 
 Reviewing transcripts      YES    NO   
 
 
Would you like to receive feedback about the overall results of this study?  
         
        YES    NO   
 
If you answered YES, please indicate your preferred form of feedback and address: 
 
 Postal:   _______________________________________________________ 
 
___________________________________________________ 
 
 Email:  ___________________________________________________ 
 
 
 
 
 
................................................................. 
Signature  
 
 
 
 .............. .................................................... 
PRINT name 
 
 
.................................................................................. 
Date 
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Appendix 5: Invitation Email for Participation 
 
 
Wording for Email/Facebook 
 
Subject: Invitation for Participation in the Research Interview 
 
 
Dear ___________ 
 
 
I am a post graduate student at The University of Sydney and I am currently 
undertaking a research project for the completion of my Master of Philosophy 
(Pharmacy) under the supervision of Dr Betty Chaar and Dr Rebekah Moles. 
 
The title of my research project is “Exploring Procurement through the lens of the 
Basel Statements: A Comparative Study Between Australia and Nepal” 
 
The objective of this research project is to explore and compare the implementation 
of the procurement guidelines based on the Basel Statements in Australia and Nepal 
and we are hoping to interview hospital pharmacists or procurement officers 
regarding current practice. 
 
Attached are the Participant Information Statement and Consent Form. We request 
that you consider participation in our research and would also be grateful if you could 
forward this information to other parties you think may be interested. If you have any 
queries concerning the nature of the research or are unclear about the extent of your 
involvement please contact me at mina.shrestha@sydney.edu.au or Betty Chaar at 
betty.chaar@sydney.edu.au or Rebekah Moles at rebekah.moles@sydney.edu.au 
 
Finally, we would like to thank you for taking the time to consider our request and we 
look forward to your reply.   
 
Yours sincerely, 
Mina Shrestha | M.Phil Candidate 
Pharmacy Practice | Faculty of Pharmacy |The University of Sydney 
Room S114 | Pharmacy and Bank Building A15 |The University of Sydney | NSW | 
2006 
T +61 293515534 | F +61 2 9351 4451  
 
 
